{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T16:27:47Z","timestamp":1794500867994,"version":"4.9.1"},"reference-count":485,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The coronavirus disease 2019 (COVID-19) pandemic has stimulated extensive endeavors toward the development of therapeutic interventions targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human proteins for viral infection control, encompassing numerous potential drugs and thousands of patients participating in clinical trials. These concerted efforts have resulted in significant advancements in antiviral drug discovery and development. In this review, we present a comprehensive timeline detailing the development of antiviral drugs, tracing the progression from early viral inhibitors to modern broad-spectrum antiviral agents. We also outline the current status of advancements in antiviral drug discovery, encompassing target-based strategies, innovative mechanism-based approaches, and pharmacokinetic optimization. Furthermore, we discuss the challenges and future prospects gained from COVID-19 and other infectious diseases, covering knowledge of artificial intelligence strategies, the utilization of medicinal chemistry tools, and advancements in nanotechnology applications. The application of artificial intelligence in drug discovery is increasingly prevalent, particularly in the areas of protein structure prediction, drug target identification, and bioactivity forecasting. Nanotechnology has played a crucial role in the delivery of antiviral drugs and the development of vaccines, exemplified by the use of lipid nanoparticles in mRNA vaccines. Additionally, we highlight potential future directions for drug discovery, such as targeting membraneless organelles (liquid\u2012liquid phase separation).<\/jats:p>","DOI":"10.1038\/s41392-025-02539-7","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:03:29Z","timestamp":1771977809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Antiviral drug discovery and development: challenges and future directions"],"prefix":"10.1038","volume":"11","author":[{"given":"Shaoqing","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3014-6719","authenticated-orcid":false,"given":"Xueping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meehyein","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-2214","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-6026","authenticated-orcid":false,"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2539_CR1","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41551-020-00658-w","volume":"4","author":"N Pardi","year":"2020","unstructured":"Pardi, N. & Weissman, D. Development of vaccines and antivirals for combating viral pandemics. Nat. Biomed. Eng. 4, 1128\u20131133 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"2539_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11111-1","volume":"21","author":"I Ayouni","year":"2021","unstructured":"Ayouni, I. et al. Effective public health measures to mitigate the spread of COVID-19: A systematic review. BMC Public Health 21, 1015 (2021).","journal-title":"BMC Public Health"},{"key":"2539_CR3","doi-asserted-by":"publisher","first-page":"666548","DOI":"10.3389\/fviro.2021.666548","volume":"1","author":"G Andrei","year":"2021","unstructured":"Andrei, G. Vaccines and antivirals: Grand challenges and great opportunities. Front. Virol. 1, 666548 (2021).","journal-title":"Front. Virol."},{"key":"2539_CR4","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1039\/D0CS01084G","volume":"50","author":"Y Ma","year":"2021","unstructured":"Ma, Y. et al. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem. Soc. Rev. 50, 4514\u20134540 (2021).","journal-title":"Chem. Soc. Rev."},{"key":"2539_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20587384211002621","volume":"35","author":"S Kausar","year":"2021","unstructured":"Kausar, S. et al. A review: Mechanism of action of antiviral drugs. Int. J. Immunopath. Pharmacol. 35, 1\u201312 (2021).","journal-title":"Int. J. Immunopath. Pharmacol."},{"key":"2539_CR6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170236","volume":"133","author":"M Karim","year":"2023","unstructured":"Karim, M., Lo, C. & Einav, S. Preparing for the next viral threat with broad-spectrum antivirals. J. Clin. Invest. 133, e170236 (2023).","journal-title":"J. Clin. Invest."},{"key":"2539_CR7","doi-asserted-by":"publisher","first-page":"e00040","DOI":"10.1128\/cmr.00040-22","volume":"36","author":"R Kumari","year":"2023","unstructured":"Kumari, R. et al. Antiviral approaches against influenza virus. Clin. Microbiol. Rev. 36, e00040\u201322 (2023).","journal-title":"Clin. Microbiol. Rev."},{"key":"2539_CR8","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/14760584.2021.1903879","volume":"20","author":"L Bian","year":"2021","unstructured":"Bian, L. et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev. Vaccines 20, 365\u2013373 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"2539_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41573-024-01102-3","volume":"24","author":"JF Demarest","year":"2025","unstructured":"Demarest, J. F. et al. Antiviral target compound profile for pandemic preparedness. Nat. Rev. Drug Discov. 24, 151\u2013152 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41573-022-00472-w","volume":"21","author":"F Vincent","year":"2022","unstructured":"Vincent, F. et al. Phenotypic drug discovery: Recent successes, lessons learned and new directions. Nat. Rev. Drug Discov. 21, 899\u2013914 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR11","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1021\/acschembio.1c00657","volume":"16","author":"Y Ayotte","year":"2021","unstructured":"Ayotte, Y. et al. Fragment-based phenotypic lead discovery to identify new drug seeds that target infectious diseases. ACS Chem. Biol. 16, 2158\u20132163 (2021).","journal-title":"ACS Chem. Biol."},{"key":"2539_CR12","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.2174\/0929867311320130004","volume":"20","author":"ML Bolognesi","year":"2013","unstructured":"Bolognesi, M. L. Polypharmacology in a single drug: Multitarget drugs. Curr. Med. Chem. 20, 1639\u20131645 (2013).","journal-title":"Curr. Med. Chem."},{"key":"2539_CR13","first-page":"D1031","volume":"48","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. Therapeutic target database 2020: Enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 48, D1031\u2013D1041 (2019).","journal-title":"Nucleic Acids Res"},{"key":"2539_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","volume":"16","author":"R Santos","year":"2017","unstructured":"Santos, R. et al. A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 16, 19\u201334 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","volume":"16","author":"JG Moffat","year":"2017","unstructured":"Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: An industry perspective. Nat. Rev. Drug Discov. 16, 531\u2013543 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR16","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.2147\/DDDT.S129447","volume":"11","author":"M Szabo","year":"2017","unstructured":"Szabo, M. et al. Cell and small animal models for phenotypic drug discovery. Drug Des. Dev. Ther. 11, 1957\u20131967 (2017).","journal-title":"Drug Des. Dev. Ther."},{"key":"2539_CR17","doi-asserted-by":"publisher","first-page":"12651","DOI":"10.1021\/acs.jmedchem.2c01737","volume":"66","author":"A Sadri","year":"2023","unstructured":"Sadri, A. Is target-based drug discovery efficient? Discovery and \u201coff-target\u201d mechanisms of all drugs. J. Med. Chem. 66, 12651\u201312677 (2023).","journal-title":"J. Med. Chem."},{"key":"2539_CR18","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.drudis.2021.01.013","volume":"26","author":"S Malandraki-Miller","year":"2021","unstructured":"Malandraki-Miller, S. & Riley, P. R. Use of artificial intelligence to enhance phenotypic drug discovery. Drug Discov. Today 26, 887\u2013901 (2021).","journal-title":"Drug Discov. Today"},{"key":"2539_CR19","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1021\/acs.jmedchem.9b00091","volume":"62","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Discovery, optimization, and target identification of novel potent broad-spectrum antiviral inhibitors. J. Med. Chem. 62, 4056\u20134073 (2019).","journal-title":"J. Med. Chem."},{"key":"2539_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie, X. et al. Recent advances in targeting the \u201cundruggable\u201d proteins: From drug discovery to clinical trials. Sig. Transduct. Tar. Ther. 8, 335 (2023).","journal-title":"Sig. Transduct. Tar. Ther."},{"key":"2539_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s43856-024-00625-5","volume":"4","author":"M Gordillo-Mara\u00f1\u00f3n","year":"2024","unstructured":"Gordillo-Mara\u00f1\u00f3n, M. et al. Disease coverage of human genome-wide association studies and pharmaceutical research and development. Commun. Med. 4, 195 (2024).","journal-title":"Commun. Med."},{"key":"2539_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1039\/C6MD00129G","volume":"7","author":"H Al-Ali","year":"2016","unstructured":"Al-Ali, H. The evolution of drug discovery: From phenotypes to targets, and back. Med. Chem. Commun. 7, 788 (2016).","journal-title":"Med. Chem. Commun."},{"key":"2539_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41587-024-02143-0","volume":"43","author":"F Ren","year":"2025","unstructured":"Ren, F. et al. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat. Biotechnol. 43, 63\u201375 (2025).","journal-title":"Nat. Biotechnol."},{"key":"2539_CR24","doi-asserted-by":"publisher","first-page":"101053","DOI":"10.1016\/j.drup.2024.101053","volume":"73","author":"S Du","year":"2024","unstructured":"Du, S., Hu, X., Men\u00e9ndez-Arias, L., Zhan, P. & Liu, X. Target-based drug design strategies to overcome resistance to antiviral agents: Opportunities and challenges. Drug Resistance Update 73, 101053 (2024).","journal-title":"Drug Resistance Update"},{"key":"2539_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: Progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13765-023-00842-x","volume":"66","author":"I Oktavianawati","year":"2023","unstructured":"Oktavianawati, I., Santoso, M., Bakar, M. F. A., Kim, Y. U. & Fatmawati, S. Recent progress on drugs discovery study for treatment of COVID-19: Repurposing existing drugs and current natural bioactive molecules. Appl. Biol. Chem. 66, 89 (2023).","journal-title":"Appl. Biol. Chem."},{"key":"2539_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41579-024-01036-y","volume":"22","author":"JFW Chan","year":"2024","unstructured":"Chan, J. F. W., Yuan, S., Chu, H., Sridhar, S. & Yuen, K. Y. COVID-19 drug discovery and treatment options. Nat. Rev. Microbiol. 22, 391\u2013407 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"2539_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/v14050961","volume":"14","author":"TI Ng","year":"2022","unstructured":"Ng, T. I. et al. Antiviral drug discovery for the treatment of COVID-19 infections. Viruses 14, 961 (2022).","journal-title":"Viruses"},{"key":"2539_CR29","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s11192-020-03707-y","volume":"125","author":"AKS Romasanta","year":"2020","unstructured":"Romasanta, A. K. S., Van Der Sijde, P. & Van Muijlwijk-Koezen, J. Innovation in pharmaceutical R&D: Mapping the research landscape. Scientometrics 125, 1801\u20131832 (2020).","journal-title":"Scientometrics"},{"key":"2539_CR30","first-page":"967","volume":"72","author":"I Stiller","year":"2022","unstructured":"Stiller, I., Van Witteloostuijn, A. & Cambr\u00e9, B. Determinants of radical drug innovation: A systematic literature review. Manag. Rev. Quart. 72, 967\u20131016 (2022).","journal-title":"Manag. Rev. Quart."},{"key":"2539_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53632-4","volume":"15","author":"K Wu","year":"2024","unstructured":"Wu, K. et al. TamGen: Drug design with target-aware molecule generation through a chemical language model. Nat. Commun. 15, 9360 (2024).","journal-title":"Nat. Commun."},{"key":"2539_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/bs.mie.2023.06.021","volume":"690","author":"MP Martin","year":"2023","unstructured":"Martin, M. P., Endicott, J. A., Noble, M. E. M. & Tatum, N. J. Crystallographic fragment screening in academic cancer drug discovery. Methods Enzymol. 690, 211\u2013234 (2023).","journal-title":"Methods Enzymol."},{"key":"2539_CR33","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/d41586-021-01571-1","volume":"594","author":"F Von Delft","year":"2021","unstructured":"Von Delft, F. et al. A white-knuckle ride of open COVID drug discovery. Nature 594, 330\u2013332 (2021).","journal-title":"Nature"},{"key":"2539_CR34","doi-asserted-by":"crossref","unstructured":"Landis, M. N. Topical and intralesional antiviral agents. Topical and Intralesional Antiviral Agents 493\u2013503 (2021).","DOI":"10.1016\/B978-0-323-61211-1.00043-7"},{"key":"2539_CR35","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.1016\/j.bmcl.2015.09.029","volume":"25","author":"A Magri","year":"2015","unstructured":"Magri, A. et al. Rethinking the old antiviral drug moroxydine: Discovery of novel analogs as anti-hepatitis C virus (HCV) agents. Bioorg. Med. Chem. Lett. 25, 5372\u20135376 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2539_CR36","doi-asserted-by":"publisher","first-page":"113378","DOI":"10.1016\/j.ejmech.2021.113378","volume":"219","author":"D Kathuria","year":"2021","unstructured":"Kathuria, D., Raul, A. D., Wanjari, P. & Bharatam, P. V. Biguanides: Species with versatile therapeutic applications. Eur. J. Med. Chem. 219, 113378 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"2539_CR37","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/aps.2011.7","volume":"32","author":"D Chen","year":"2011","unstructured":"Chen, D. et al. Novel liver-specific cholic acid-cytarabine conjugates with potent antitumor activities: Synthesis and biological characterization. Acta Pharmacol. Sin. 32, 664\u2013672 (2011).","journal-title":"Acta Pharmacol. Sin."},{"key":"2539_CR38","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.13719","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Cyclocytidine hydrochloride inhibits the synthesis of relaxed circular DNA of hepatitis B virus. Peer J. 10, e13719 (2022).","journal-title":"Peer J."},{"key":"2539_CR39","doi-asserted-by":"publisher","first-page":"12810","DOI":"10.3390\/ijms252312810","volume":"25","author":"X Gao","year":"2024","unstructured":"Gao, X. et al. A potential use of vidarabine: Alleviation of functional constipation through modulation of the adenosine A2A receptor-MLC signaling pathway and the gut microbiota. Int. J. Mol. Sci. 25, 12810 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2539_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijpharm.2018.09.043","volume":"552","author":"R Liu","year":"2018","unstructured":"Liu, R. et al. A preclinical evaluation of cytarabine prodrug nanofibers assembled from cytarabine-lauric acid conjugate toward solid tumors. Int. J. Pharm. 552, 111\u2013118 (2018).","journal-title":"Int. J. Pharm."},{"key":"2539_CR41","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/nsr\/nwz006","volume":"6","author":"Y Hu","year":"2019","unstructured":"Hu, Y. et al. Ecological principle meets cancer treatment: treating children with acute myeloid leukemia with low-dose chemotherapy. Natl. Sci. Rev. 6, 469\u2013479 (2019).","journal-title":"Natl. Sci. Rev."},{"key":"2539_CR42","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003495-198937030-00002","volume":"37","author":"JJ O\u2019Brien","year":"1989","unstructured":"O\u2019Brien, J. J. & Campoli-Richards, D. M. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 37, 233\u2013309 (1989).","journal-title":"Drugs"},{"key":"2539_CR43","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2165\/00003495-198937040-00003","volume":"37","author":"HD Langtry","year":"1989","unstructured":"Langtry, H. D. & Campoli-Richards, D. M. Zidovudine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 37, 408\u2013450 (1989).","journal-title":"Drugs"},{"key":"2539_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1386-6532(02)00151-8","volume":"25","author":"SML Waugh","year":"2002","unstructured":"Waugh, S. M. L., Pillay, D., Carrington, D. & Carman, W. F. Antiviral prophylaxis and treatment (excluding HIV therapy). J. Clin. Virol. 25, 241\u2013266 (2002).","journal-title":"J. Clin. Virol."},{"key":"2539_CR45","doi-asserted-by":"publisher","first-page":"843032","DOI":"10.3389\/fonc.2022.843032","volume":"12","author":"G Zheng","year":"2022","unstructured":"Zheng, G. et al. Efficacy of intermittent, oral famciclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Front. Oncol. 12, 843032 (2022).","journal-title":"Front. Oncol."},{"key":"2539_CR46","doi-asserted-by":"crossref","unstructured":"Mondal, D. Penciclovir. xPharm: The Comprehensive Pharmacology Reference, 1\u20134 (2007).","DOI":"10.1016\/B978-008055232-3.62383-9"},{"key":"2539_CR47","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1039\/D3SC06800E","volume":"15","author":"J Meng","year":"2024","unstructured":"Meng, J., Su, Y., Zhu, H. & Cai, T. Shape memory and self-healing in a molecular crystal with inverse temperature symmetry breaking. Chem. Sci. 15, 5738\u20135745 (2024).","journal-title":"Chem. Sci."},{"key":"2539_CR48","first-page":"123","volume":"118","author":"KDP Hammer","year":"2018","unstructured":"Hammer, K. D. P., Dietz, J., Shien Lo, T. & Johnson, E. M. A systematic review on the efficacy of topical acyclovir, penciclovir, and docosanol for the treatment of herpes simplex labialis. EMJ Dermatol 118, 123 (2018).","journal-title":"EMJ Dermatol"},{"key":"2539_CR49","doi-asserted-by":"publisher","first-page":"9","DOI":"10.12688\/f1000research.5827.2","volume":"4","author":"T Koltai","year":"2015","unstructured":"Koltai, T. Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. F1000Research 4, 9 (2015).","journal-title":"F1000Research"},{"key":"2539_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05282-w","volume":"22","author":"N Hosogaya","year":"2021","unstructured":"Hosogaya, N. et al. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: A structured summary of a study protocol for a multicenter, randomized controlled trial. Trials 22, 309 (2021).","journal-title":"Trials"},{"key":"2539_CR51","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/jmv.25985","volume":"92","author":"F Musarrat","year":"2020","unstructured":"Musarrat, F. et al. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARS-CoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. J. Med. Virol. 92, 2087\u20132095 (2020).","journal-title":"J. Med. Virol."},{"key":"2539_CR52","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMcibr2007042","volume":"382","author":"JM Parks","year":"2020","unstructured":"Parks, J. M. & Smith, J. C. How to discover antiviral drugs quickly. N. Engl. J. Med. 382, 2261\u20132264 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2539_CR53","doi-asserted-by":"publisher","first-page":"103679","DOI":"10.1016\/j.amsu.2022.103679","volume":"77","author":"A Zendehdel","year":"2022","unstructured":"Zendehdel, A., Bidkhori, M., Ansari, M., Jamalimoghaddamsiyahkali, S. & Asoodeh, A. Efficacy of oseltamivir in the treatment of patients infected with COVID-19. Ann. Med. Surg. 77, 103679 (2022).","journal-title":"Ann. Med. Surg."},{"key":"2539_CR54","doi-asserted-by":"publisher","first-page":"107111","DOI":"10.1016\/j.ijantimicag.2024.107111","volume":"63","author":"C Leung","year":"2024","unstructured":"Leung, C., Su, L., Taylor, L., Oliveira, E. A. & Silva, A. C. S. e. Effectiveness of oseltamivir in reducing COVID-19-related in-hospital deaths: A pharmacoepidemiological study. Int. J. Antimicrob. Ag. 63, 107111 (2024).","journal-title":"Int. J. Antimicrob. Ag."},{"key":"2539_CR55","doi-asserted-by":"publisher","first-page":"g2545","DOI":"10.1136\/bmj.g2545","volume":"348","author":"T Jefferson","year":"2014","unstructured":"Jefferson, T. et al. Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ 348, g2545 (2014).","journal-title":"BMJ"},{"key":"2539_CR56","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/cts.12697","volume":"13","author":"P Zuo","year":"2020","unstructured":"Zuo, P. et al. Population pharmacokinetic\/pharmacodynamic analysis of intravenous zanamivir in healthy adults and hospitalized adult and pediatric subjects with influenza. Clin. Transl. Sci. 13, 157\u2013168 (2020).","journal-title":"Clin. Transl. Sci."},{"key":"2539_CR57","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/infdis\/jit467","volume":"209","author":"FM Marty","year":"2014","unstructured":"Marty, F. M. et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: An open-label, multicenter, single-arm, phase II study. J. Infect. Dis. 209, 542\u2013550 (2014).","journal-title":"J. Infect. Dis."},{"key":"2539_CR58","doi-asserted-by":"publisher","first-page":"g2547","DOI":"10.1136\/bmj.g2547","volume":"348","author":"CJ Heneghan","year":"2014","unstructured":"Heneghan, C. J. et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 348, g2547 (2014).","journal-title":"BMJ"},{"key":"2539_CR59","doi-asserted-by":"publisher","first-page":"1294966","DOI":"10.3389\/fphar.2023.1294966","volume":"14","author":"Y Peng","year":"2023","unstructured":"Peng, Y. et al. Current drugs for HIV-1: From challenges to potential in HIV\/AIDS. Front. Pharmacol. 14, 1294966 (2023).","journal-title":"Front. Pharmacol."},{"key":"2539_CR60","doi-asserted-by":"publisher","first-page":"102457","DOI":"10.1016\/j.eclinm.2024.102457","volume":"69","author":"NI Paton","year":"2024","unstructured":"Paton, N. I. et al. Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomized, controlled, open-label pragmatic trial (PIVOT). eClinicalMedicine 69, 102457 (2024).","journal-title":"eClinicalMedicine"},{"key":"2539_CR61","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1080\/13543784.2016.1212837","volume":"25","author":"NM Midde","year":"2016","unstructured":"Midde, N. M., Patters, B. J., Rao, P., Cory, T. J. & Kumar, S. Investigational protease inhibitors as antiretroviral therapies. Expert Opin. Investig. Drug. 25, 1189\u20131200 (2016).","journal-title":"Expert Opin. Investig. Drug."},{"key":"2539_CR62","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11904-019-00480-3","volume":"17","author":"J Trivedi","year":"2020","unstructured":"Trivedi, J. et al. Recent advances in the development of integrase inhibitors for HIV treatment. Curr. HIV\/AIDS Rep. 17, 63\u201375 (2020).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"2539_CR63","doi-asserted-by":"publisher","first-page":"107294","DOI":"10.1016\/j.ijantimicag.2024.107294","volume":"64","author":"S Liu","year":"2024","unstructured":"Liu, S., Yuan, D., Zhou, Y., Wang, B. & Hu, H. Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations. Int. J. Antimicrob. Ag. 64, 107294 (2024).","journal-title":"Int. J. Antimicrob. Ag."},{"key":"2539_CR64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/v13020205","volume":"13","author":"SJ Smith","year":"2021","unstructured":"Smith, S. J. et al. Integrase strand transfer inhibitors are effective anti-HIV drugs. Viruses 13, 205 (2021).","journal-title":"Viruses"},{"key":"2539_CR65","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","volume":"12","author":"G Li","year":"2022","unstructured":"Li, G., Wang, Y. & De Clercq, E. Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharm. Sin. B 12, 1567\u20131590 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"2539_CR66","doi-asserted-by":"publisher","first-page":"9028","DOI":"10.3390\/ijms25169028","volume":"25","author":"Z Zhuo","year":"2024","unstructured":"Zhuo, Z. et al. Discovery of novel amino acids (analogs)-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors: Design, synthesis, and biological evaluation. Int. J. Mol. Sci. 25, 9028 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2539_CR67","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.bpj.2018.02.038","volume":"114","author":"RE Amaro","year":"2018","unstructured":"Amaro, R. E. et al. Ensemble docking in drug discovery. Biophys. J. 114, 2271\u20132278 (2018).","journal-title":"Biophys. J."},{"key":"2539_CR68","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1146\/annurev-biochem-030222-120000","volume":"93","author":"JM Paggi","year":"2024","unstructured":"Paggi, J. M., Pandit, A. & Dror, R. O. The art and science of molecular docking. Annu. Rev. Biochem. 93, 389\u2013410 (2024).","journal-title":"Annu. Rev. Biochem."},{"key":"2539_CR69","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.coph.2016.07.015","volume":"30","author":"JA McCauley","year":"2016","unstructured":"McCauley, J. A. & Rudd, M. T. Hepatitis C virus NS3\/4a protease inhibitors. Curr. Opin. Pharmacol. 30, 84\u201392 (2016).","journal-title":"Curr. Opin. Pharmacol."},{"key":"2539_CR70","doi-asserted-by":"publisher","first-page":"e02680","DOI":"10.1128\/AAC.02680-20","volume":"65","author":"KA Gammeltoft","year":"2021","unstructured":"Gammeltoft, K. A. et al. Hepatitis C virus protease inhibitors show differential efficacy and interactions with remdesivir for treatment of SARS-CoV-2 in vitro. Antimicrob. Agents Chemother. 65, e02680\u201320 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2539_CR71","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.3390\/v7102868","volume":"7","author":"A Eltahla","year":"2015","unstructured":"Eltahla, A., Luciani, F., White, P., Lloyd, A. & Bull, R. Inhibitors of the Hepatitis C virus polymerase; Mode of action and resistance. Viruses 7, 5206\u20135224 (2015).","journal-title":"Viruses"},{"key":"2539_CR72","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1056\/NEJMra1213651","volume":"368","author":"TJ Liang","year":"2013","unstructured":"Liang, T. J. & Ghany, M. G. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 368, 1907\u20131917 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2539_CR73","first-page":"239","volume":"91","author":"A Nourian","year":"2020","unstructured":"Nourian, A. & Khalili, H. Sofosbuvir as a potential option for the treatment of COVID-19. Acta Biomed. 91, 239\u2013241 (2020).","journal-title":"Acta Biomed."},{"key":"2539_CR74","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.arcmed.2020.04.018","volume":"51","author":"B Sayad","year":"2020","unstructured":"Sayad, B., Sobhani, M. & Khodarahmi, R. Sofosbuvir as repurposed antiviral drug against COVID-19: Why were we convinced to evaluate the drug in a registered\/approved clinical trial?. Arch. Med. Res. 51, 577\u2013581 (2020).","journal-title":"Arch. Med. Res."},{"key":"2539_CR75","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1093\/jac\/dkab152","volume":"76","author":"B Sayad","year":"2021","unstructured":"Sayad, B. et al. Efficacy and safety of sofosbuvir\/velpatasvir versus the standard of care in adults hospitalized with COVID-19: A single-center, randomized controlled trial. J. Antimicrob. Chemother. 76, 2158\u20132167 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"2539_CR76","doi-asserted-by":"crossref","unstructured":"Sofia, M. J. & Furman, P. A. The discovery of sofosbuvir: A liver-targeted nucleotide prodrug for the treatment and cure of HCV. HCV: The journey from discovery to a cure. 141\u2013170 (2019).","DOI":"10.1007\/7355_2018_37"},{"key":"2539_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00170-x","volume":"8","author":"D Roymans","year":"2017","unstructured":"Roymans, D. et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat. Commun. 8, 167 (2017).","journal-title":"Nat. Commun."},{"key":"2539_CR78","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nchembio.1982","volume":"12","author":"MB Battles","year":"2016","unstructured":"Battles, M. B. et al. Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat. Chem. Biol. 12, 87\u201393 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"2539_CR79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40360-018-0212-7","volume":"19","author":"N Chen","year":"2018","unstructured":"Chen, N. et al. Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: A comparative study of Chinese and foreign case series. BMC Pharmacol. Toxicol. 19, 23 (2018).","journal-title":"BMC Pharmacol. Toxicol."},{"key":"2539_CR80","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2147\/DDDT.S192632","volume":"13","author":"YY Qian","year":"2019","unstructured":"Qian, Y. Y. et al. Low-dose adefovir dipivoxil-induced hypophosphatemia osteomalacia in five chronic hepatitis B virus-infected patients. Is low-dose adefovir dipivoxil-induced nephrotoxicity completely reversible? Drug Des. Dev. Ther. 13, 1127\u20131133 (2019).","journal-title":"Dev. Ther."},{"key":"2539_CR81","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.3748\/wjg.v21.i12.3657","volume":"21","author":"HY Jia","year":"2015","unstructured":"Jia, H. Y. et al. Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B. World J. Gastroenterol. 21, 3657\u20133662 (2015).","journal-title":"World J. Gastroenterol."},{"key":"2539_CR82","first-page":"13","volume":"8","author":"J Wang","year":"2014","unstructured":"Wang, J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des. Dev. Ther. 8, 13\u201324 (2014).","journal-title":"Drug Des. Dev. Ther."},{"key":"2539_CR83","first-page":"51","volume":"1","author":"H Tang","year":"2013","unstructured":"Tang, H., Griffin, J., Innaimo, S., Lehman-McKeeman, L. & Llamoso, C. The discovery and development of a potent antiviral drug, entecavir, for the treatment of chronic hepatitis B. J. Clin. Transl. Hepatol. 1, 51\u201358 (2013).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"2539_CR84","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrd1780","volume":"4","author":"CK Opio","year":"2005","unstructured":"Opio, C. K., Lee, W. M. & Kirkpatrick, P. Entecavir. Nat. Rev. Drug Discov. 4, 535\u2013536 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR85","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3748\/wjg.v27.i8.666","volume":"27","author":"GQ Yin","year":"2021","unstructured":"Yin, G. Q., Li, J., Zhong, B., Yang, Y. F. & Wang, M. R. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World J. Gastroenterol. 27, 666\u2013676 (2021).","journal-title":"World J. Gastroenterol."},{"key":"2539_CR86","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3390\/ph16111603","volume":"16","author":"T Louren\u00e7o","year":"2023","unstructured":"Louren\u00e7o, T. & Vale, N. Entecavir: A review and considerations for its application in oncology. Pharmaceuticals 16, 1603 (2023).","journal-title":"Pharmaceuticals"},{"key":"2539_CR87","doi-asserted-by":"publisher","first-page":"100030","DOI":"10.1016\/j.cellin.2022.100030","volume":"1","author":"Z Xu","year":"2022","unstructured":"Xu, Z. et al. Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus. Cell Insight 1, 100030 (2022).","journal-title":"Cell Insight"},{"key":"2539_CR88","first-page":"123","volume":"9","author":"A Frediansyah","year":"2021","unstructured":"Frediansyah, A., Nainu, F., Dhama, K., Mudatsir, M. & Harapan, H. Remdesivir and its antiviral activity against COVID-19: A systematic review. Clin. Epidemiol. Glob. 9, 123\u2013127 (2021).","journal-title":"Clin. Epidemiol. Glob."},{"key":"2539_CR89","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3390\/v15051167","volume":"15","author":"K Akinosoglou","year":"2023","unstructured":"Akinosoglou, K. et al. Remdesivir use in the real-world setting: An overview of available evidence. Viruses 15, 1167 (2023).","journal-title":"Viruses"},{"key":"2539_CR90","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman, R. T. et al. Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent. Sci. 6, 672\u2013683 (2020).","journal-title":"ACS Cent. Sci."},{"key":"2539_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08525-0","volume":"23","author":"C Chen","year":"2023","unstructured":"Chen, C. et al. The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: A systematic review and meta-analysis. BMC Infect. Dis. 23, 672 (2023).","journal-title":"BMC Infect. Dis."},{"key":"2539_CR92","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s43856-024-00650-4","volume":"4","author":"TDJH Patrick-Brown","year":"2024","unstructured":"Patrick-Brown, T. D. J. H. et al. The effects of remdesivir on long-term symptoms in patients hospitalized for COVID-19: A prespecified exploratory analysis. Commun. Med. 4, 231 (2024).","journal-title":"Commun. Med."},{"key":"2539_CR93","doi-asserted-by":"publisher","first-page":"105970","DOI":"10.1016\/j.antiviral.2024.105970","volume":"230","author":"R Rosales","year":"2024","unstructured":"Rosales, R. et al. Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants. Antivir. Res. 230, 105970 (2024).","journal-title":"Antivir. Res."},{"key":"2539_CR94","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","volume":"31","author":"RP Joyce","year":"2022","unstructured":"Joyce, R. P., Hu, V. W. & Wang, J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): An orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med. Chem. Res. 31, 1637\u20131646 (2022).","journal-title":"Med. Chem. Res."},{"key":"2539_CR95","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/cid\/ciae336","volume":"79","author":"D Fusco","year":"2024","unstructured":"Fusco, D. et al. Remdesivir for treatment of COVID-19 requiring oxygen support: A cross-study comparison from 2 large, open-label studies. Clin. Infect. Dis. 79, 1182\u20131189 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"2539_CR96","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1128\/CMR.00102-15","volume":"29","author":"E De Clercq","year":"2016","unstructured":"De Clercq, E. & Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695\u2013747 (2016).","journal-title":"Clin. Microbiol. Rev."},{"key":"2539_CR97","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41586-023-06388-8","volume":"620","author":"K Trajanoska","year":"2023","unstructured":"Trajanoska, K. et al. From target discovery to clinical drug development with human genetics. Nature 620, 737\u2013745 (2023).","journal-title":"Nature"},{"key":"2539_CR98","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/nrd.2016.184","volume":"15","author":"RK Harrison","year":"2016","unstructured":"Harrison, R. K. Phase II and phase III failures: 2013\u20132015. Nat. Rev. Drug Discov. 15, 817\u2013818 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR99","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrd4090","volume":"12","author":"J Arrowsmith","year":"2013","unstructured":"Arrowsmith, J. & Miller, P. Phase II and Phase III attrition rates 2011\u20132012. Nat. Rev. Drug Discov. 12, 569\u2013569 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR100","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA 323, 844 (2020).","journal-title":"JAMA"},{"key":"2539_CR101","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1021\/acs.jmedchem.1c00048","volume":"64","author":"M Rossi","year":"2021","unstructured":"Rossi, M. et al. Sustainable drug discovery of multi-target-directed ligands for Alzheimer\u2019s disease. J. Med. Chem. 64, 4972\u20134990 (2021).","journal-title":"J. Med. Chem."},{"key":"2539_CR102","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","volume":"31","author":"K Zhang","year":"2025","unstructured":"Zhang, K. et al. Artificial intelligence in drug development. Nat. Med. 31, 45\u201359 (2025).","journal-title":"Nat. Med."},{"key":"2539_CR103","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eng.2018.11.011","volume":"5","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Artemisinin, the magic drug discovered from traditional Chinese medicine. Engineering 5, 32\u201339 (2019).","journal-title":"Engineering"},{"key":"2539_CR104","doi-asserted-by":"publisher","first-page":"101976","DOI":"10.1016\/j.xcrm.2025.101976","volume":"6","author":"J Li","year":"2025","unstructured":"Li, J. et al. Pharmacological rescue of mutant p53 triggers spontaneous tumor regression via immune responses. Cell Rep. Med. 6, 101976 (2025).","journal-title":"Cell Rep. Med."},{"key":"2539_CR105","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd4309","volume":"13","author":"D Cook","year":"2014","unstructured":"Cook, D. et al. Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: A five-dimensional framework. Nat. Rev. Drug Discov. 13, 419\u2013431 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR106","doi-asserted-by":"publisher","unstructured":"Spotlight on cancer genomics. Nat. Cancer 1, 265\u2013266 (2020). https:\/\/doi.org\/10.1038\/s43018-020-0052-4.","DOI":"10.1038\/s43018-020-0052-4"},{"key":"2539_CR107","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 28, 165\u2013173 (2020).","journal-title":"Eur. J. Hum. Genet."},{"key":"2539_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0703-1","volume":"12","author":"ER Malone","year":"2020","unstructured":"Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L. & Siu, L. L. Molecular profiling for precision cancer therapies. Genome Med. 12, 8 (2020).","journal-title":"Genome Med."},{"key":"2539_CR109","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ajhg.2022.12.011","volume":"110","author":"A Abdellaoui","year":"2023","unstructured":"Abdellaoui, A., Yengo, L., Verweij, K. J. H. & Visscher, P. M. 15 years of GWAS discovery: Realizing the promise. Am. J. Hum. Genet. 110, 179\u2013194 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"2539_CR110","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154943","volume":"132","author":"MR Waarts","year":"2022","unstructured":"Waarts, M. R., Stonestrom, A. J., Park, Y. C. & Levine, R. L. Targeting mutations in cancer. J. Clin. Invest. 132, e154943 (2022).","journal-title":"J. Clin. Invest."},{"key":"2539_CR111","doi-asserted-by":"publisher","first-page":"115691","DOI":"10.1016\/j.ab.2024.115691","volume":"697","author":"Y Zuo","year":"2025","unstructured":"Zuo, Y. et al. Research progress on drug-target interactions in the last five years. Anal. Biochem. 697, 115691 (2025).","journal-title":"Anal. Biochem."},{"key":"2539_CR112","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"J Hughes","year":"2011","unstructured":"Hughes, J., Rees, S., Kalindjian, S. & Philpott, K. Principles of early drug discovery. Brit. J. Pharmacol. 162, 1239\u20131249 (2011).","journal-title":"Brit. J. Pharmacol."},{"key":"2539_CR113","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41392-021-00508-4","volume":"6","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Multiplatform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery. Sig. Transduct. Target. Ther. 6, 155 (2021).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR114","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-022-00994-0","volume":"7","author":"Y You","year":"2022","unstructured":"You, Y. et al. Artificial intelligence in cancer target identification and drug discovery. Sig. Transduct. Target. Ther. 7, 156 (2022).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-023-00815-4","volume":"23","author":"Y Tabana","year":"2023","unstructured":"Tabana, Y., Babu, D., Fahlman, R., Siraki, A. G. & Barakat, K. Target identification of small molecules: an overview of the current applications in drug discovery. BMC Biotechnol. 23, 44 (2023).","journal-title":"BMC Biotechnol."},{"key":"2539_CR116","doi-asserted-by":"crossref","unstructured":"Popova, L. & Carabetta, V. J. The use of next-generation sequencing in personalized medicine. High Throughput Gene Screening: Methods and Protocols. 287\u2013316 (2025).","DOI":"10.1007\/978-1-0716-4192-7_16"},{"key":"2539_CR117","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-anchem-071213-020216","volume":"7","author":"Z Zhang","year":"2014","unstructured":"Zhang, Z., Wu, S., Stenoien, D. L. & Pas\u01ce-Tolic, L. High-throughput proteomics. Annu. Rev. Anal. Chem. 7, 427\u2013454 (2014).","journal-title":"Annu. Rev. Anal. Chem."},{"key":"2539_CR118","doi-asserted-by":"publisher","first-page":"113844","DOI":"10.1016\/j.addr.2021.113844","volume":"176","author":"Q Xiao","year":"2021","unstructured":"Xiao, Q. et al. High-throughput proteomics and AI for cancer biomarker discovery. Adv. Drug Deliv. Rev. 176, 113844 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2539_CR119","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2174\/1568026617666161116143440","volume":"17","author":"X Xia","year":"2017","unstructured":"Xia, X. Bioinformatics and Drug Discovery. Curr. Top. Med. Chem. 17, 1709\u20131726 (2017).","journal-title":"Curr. Top. Med. Chem."},{"key":"2539_CR120","doi-asserted-by":"publisher","first-page":"292","DOI":"10.31083\/j.rcm2508292","volume":"25","author":"L Yang","year":"2024","unstructured":"Yang, L. et al. Causal relationships between lipid-lowering drug target and aortic disease and calcific aortic valve stenosis: A two-sample mendelian randomization. Rev. Cardiovasc. Med. 25, 292 (2024).","journal-title":"Rev. Cardiovasc. Med."},{"key":"2539_CR121","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41573-020-0087-3","volume":"20","author":"CH Emmerich","year":"2021","unstructured":"Emmerich, C. H. et al. Improving target assessment in biomedical research: The GOT-IT recommendations. Nat. Rev. Drug Discov. 20, 64\u201381 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR122","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.drudis.2014.12.016","volume":"20","author":"JD Moore","year":"2015","unstructured":"Moore, J. D. The impact of CRISPR\u2013Cas9 on target identification and validation. Drug Discov. Today 20, 450\u2013457 (2015).","journal-title":"Drug Discov. Today"},{"key":"2539_CR123","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s10038-017-0376-9","volume":"63","author":"M Kurata","year":"2018","unstructured":"Kurata, M., Yamamoto, K., Moriarity, B. S., Kitagawa, M. & Largaespada, D. A. CRISPR\/Cas9 library screening for drug target discovery. J. Hum. Genet. 63, 179\u2013186 (2018).","journal-title":"J. Hum. Genet."},{"key":"2539_CR124","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. In vitro and in vivo evaluation of virus-induced innate immunity in mouse. Antiviral Innate Immunity 237\u2013252 (2025). https:\/\/link.springer.com\/book\/10.1007\/978-1-0716-4108-8.","DOI":"10.1007\/978-1-0716-4108-8_23"},{"key":"2539_CR125","doi-asserted-by":"publisher","first-page":"117141","DOI":"10.1016\/j.ejmech.2024.117141","volume":"283","author":"B Cheng","year":"2025","unstructured":"Cheng, B. et al. Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020\u20132024). Eur. J. Med. Chem. 283, 117141 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"2539_CR126","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41586-024-07950-8","volume":"633","author":"CSC Ng","year":"2024","unstructured":"Ng, C. S. C., Liu, A., Cui, B. & Banik, S. M. Targeted protein relocalization via protein transport coupling. Nature 633, 941\u2013951 (2024).","journal-title":"Nature"},{"key":"2539_CR127","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","volume":"7","author":"L Zhao","year":"2022","unstructured":"Zhao, L., Zhao, J., Zhong, K., Tong, A. & Jia, D. Targeted protein degradation: Mechanisms, strategies and application. Sig. Transduct. Target. Ther. 7, 113 (2022).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR128","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s42003-023-05006-7","volume":"6","author":"L Sokol","year":"2023","unstructured":"Sokol, L. et al. Prioritization and functional validation of target genes from single-cell transcriptomics studies. Commun. Biol. 6, 648 (2023).","journal-title":"Commun. Biol."},{"key":"2539_CR129","first-page":"72","volume":"59","author":"DS Sim","year":"2016","unstructured":"Sim, D. S. & Kauser, K. In vivo target validation using biological molecules in drug development. N. Approaches Drug Discov. 59, 72 (2016).","journal-title":"N. Approaches Drug Discov."},{"key":"2539_CR130","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s11655-023-3559-6","volume":"30","author":"M Feng","year":"2024","unstructured":"Feng, M. et al. Rheum palmatum L. and Salvia miltiorrhiza Bge. alleviates acute pancreatitis by regulating Th17 cell differentiation: An integrated network pharmacology analysis, molecular dynamics simulation and experimental validation. Chin. J. Integr. Med. 30, 408\u2013420 (2024).","journal-title":"Chin. J. Integr. Med."},{"key":"2539_CR131","doi-asserted-by":"publisher","first-page":"104898","DOI":"10.1016\/j.antiviral.2020.104898","volume":"182","author":"BJ Burwitz","year":"2020","unstructured":"Burwitz, B. J., Zhou, Z. & Li, W. Animal models for the study of human hepatitis B and D virus infection: New insights and progress. Antivir. Res. 182, 104898 (2020).","journal-title":"Antivir. Res."},{"key":"2539_CR132","first-page":"461","volume":"5","author":"T Kawai","year":"2014","unstructured":"Kawai, T. & Kawai, T. Toll-like receptor signaling pathways. Front. Immunol. 5, 461 (2014).","journal-title":"Front. Immunol."},{"key":"2539_CR133","doi-asserted-by":"publisher","first-page":"660809","DOI":"10.3389\/fdgth.2021.660809","volume":"3","author":"S Das","year":"2021","unstructured":"Das, S. et al. Combinatorial analysis of phenotypic and clinical risk factors associated with hospitalized COVID-19 patients. Front. Digit. Health 3, 660809 (2021).","journal-title":"Front. Digit. Health"},{"key":"2539_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03815-8","volume":"20","author":"S Das","year":"2022","unstructured":"Das, S., Taylor, K., Kozubek, J., Sardell, J. & Gardner, S. Genetic risk factors for ME\/CFS identified using combinatorial analysis. J. Transl. Med. 20, 598 (2022).","journal-title":"J. Transl. Med."},{"key":"2539_CR135","doi-asserted-by":"publisher","first-page":"935933","DOI":"10.3389\/fviro.2022.935933","volume":"2","author":"R Badia","year":"2022","unstructured":"Badia, R., Garcia-Vidal, E. & Ballana, E. Viral-host dependency factors as therapeutic targets to overcome antiviral drug-resistance: A focus on innate immune modulation. Front. Virol. 2, 935933 (2022).","journal-title":"Front. Virol."},{"key":"2539_CR136","doi-asserted-by":"publisher","first-page":"116069","DOI":"10.1016\/j.ejmech.2023.116069","volume":"265","author":"Y He","year":"2024","unstructured":"He, Y. Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses. Eur. J. Med. Chem. 265, 116069 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2539_CR137","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/microorganisms12030600","volume":"12","author":"J Wang","year":"2024","unstructured":"Wang, J., Zhu, Q., Xing, X. & Sun, D. A mini-review on the common antiviral drug targets of coronavirus. Microorganisms 12, 600 (2024).","journal-title":"Microorganisms"},{"key":"2539_CR138","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1080\/22221751.2022.2071175","volume":"11","author":"N Chen","year":"2022","unstructured":"Chen, N., Zhang, B., Deng, L., Liang, B. & Ping, J. Virus\u2012host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2. Emerg. Microbes Infect. 11, 1371\u20131389 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"2539_CR139","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.3390\/v7062771","volume":"7","author":"CW Sze","year":"2015","unstructured":"Sze, C. W. & Tan, Y. J. Viral membrane channels: Role and function in the virus life cycle. Viruses 7, 3261\u20133284 (2015).","journal-title":"Viruses"},{"key":"2539_CR140","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41591-021-01282-0","volume":"27","author":"RM Meganck","year":"2021","unstructured":"Meganck, R. M. & Baric, R. S. Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases. Nat. Med. 27, 401\u2013410 (2021).","journal-title":"Nat. Med."},{"key":"2539_CR141","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/v14050928","volume":"14","author":"Y Zheng","year":"2022","unstructured":"Zheng, Y. et al. A broad antiviral strategy: Inhibitors of human DHODH pave the way for host-targeting antivirals against emerging and re-emerging viruses. Viruses 14, 928 (2022).","journal-title":"Viruses"},{"key":"2539_CR142","doi-asserted-by":"publisher","first-page":"116356","DOI":"10.1016\/j.bmc.2021.116356","volume":"46","author":"S Mahajan","year":"2021","unstructured":"Mahajan, S., Choudhary, S., Kumar, P. & Tomar, S. Antiviral strategies targeting host factors and mechanisms obliging +ssRNA viral pathogens. Bioorg. Med. Chem. 46, 116356 (2021).","journal-title":"Bioorg. Med. Chem."},{"key":"2539_CR143","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3390\/v15030776","volume":"15","author":"VC Roa-Linares","year":"2023","unstructured":"Roa-Linares, V. C., Escudero-Fl\u00f3rez, M., Vicente-Manzanares, M. & Gallego-G\u00f3mez, J. C. Host cell targets for unconventional antivirals against RNA viruses. Viruses 15, 776 (2023).","journal-title":"Viruses"},{"key":"2539_CR144","doi-asserted-by":"publisher","first-page":"e01372","DOI":"10.1128\/mBio.01372-19","volume":"10","author":"DP Strange","year":"2019","unstructured":"Strange, D. P. et al. Axl promotes Zika virus entry and modulates the antiviral state of human sertoli cells. mBio 10, e01372\u201319 (2019).","journal-title":"mBio"},{"key":"2539_CR145","doi-asserted-by":"publisher","first-page":"575346","DOI":"10.3389\/fcimb.2021.575346","volume":"11","author":"S Xie","year":"2021","unstructured":"Xie, S., Zhang, H., Liang, Z., Yang, X. & Cao, R. AXL, an important host factor for DENV and ZIKV replication. Front. Cell Infect. Microbiol. 11, 575346 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2539_CR146","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nm.2145","volume":"16","author":"ML Weller","year":"2010","unstructured":"Weller, M. L. et al. Epidermal growth factor receptor is a coreceptor for adeno-associated virus serotype 6. Nat. Med. 16, 662\u2013664 (2010).","journal-title":"Nat. Med."},{"key":"2539_CR147","doi-asserted-by":"publisher","first-page":"107973","DOI":"10.1016\/j.bioorg.2024.107973","volume":"153","author":"ND Mao","year":"2024","unstructured":"Mao, N. D. et al. Design, synthesis, and biological evaluation of novel AAK1\/HDACs dual inhibitors against SARS-CoV-2 entry. Bioorg. Chem. 153, 107973 (2024).","journal-title":"Bioorg. Chem."},{"key":"2539_CR148","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","volume":"11","author":"R Xiong","year":"2020","unstructured":"Xiong, R. et al. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly emerged coronavirus SARS-CoV-2. Protein Cell 11, 723\u2013739 (2020).","journal-title":"Protein Cell"},{"key":"2539_CR149","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41586-021-03493-4","volume":"594","author":"A Stukalov","year":"2021","unstructured":"Stukalov, A. et al. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV. Nature 594, 246\u2013252 (2021).","journal-title":"Nature"},{"key":"2539_CR150","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg5211","volume":"9","author":"M Kuang","year":"2023","unstructured":"Kuang, M. et al. XAF1 promotes anti-RNA virus immune responses by regulating chromatin accessibility. Sci. Adv. 9, eadg5211 (2023).","journal-title":"Sci. Adv."},{"key":"2539_CR151","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.4014\/jmb.2403.03008","volume":"34","author":"W Hangyu","year":"2024","unstructured":"Hangyu, W. et al. Advancements in antiviral drug development: Comprehensive insights into design strategies and mechanisms targeting key viral proteins. J. Microbiol. Biotechnol. 34, 1376\u20131384 (2024).","journal-title":"J. Microbiol. Biotechnol."},{"key":"2539_CR152","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout, A., Katz, J. D., Venkatraman, S. & Ablasser, A. The cGAS\u2013STING pathway as a therapeutic target in inflammatory diseases. Nat. Rev. Immunol. 21, 548\u2013569 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"2539_CR153","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1038\/s12276-021-00691-y","volume":"53","author":"K Chathuranga","year":"2021","unstructured":"Chathuranga, K., Weerawardhana, A., Dodantenna, N. & Lee, J. S. Regulation of antiviral innate immune signaling and viral evasion following viral genome sensing. Exp. Mol. Med. 53, 1647\u20131668 (2021).","journal-title":"Exp. Mol. Med."},{"key":"2539_CR154","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3390\/v13061115","volume":"13","author":"Z Bai","year":"2021","unstructured":"Bai, Z., Cao, Y., Liu, W. & Li, J. The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation. Viruses 13, 1115 (2021).","journal-title":"Viruses"},{"key":"2539_CR155","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41392-024-02036-3","volume":"9","author":"H Nada","year":"2024","unstructured":"Nada, H. et al. New insights into protein\u2013protein interaction modulators in drug discovery and therapeutic advance. Sig. Transduct. Target. Ther. 9, 341 (2024).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR156","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48800-5","volume":"15","author":"S Schiefer","year":"2024","unstructured":"Schiefer, S. & Hale, B. G. Proximal protein landscapes of the type I interferon signaling cascade reveal negative regulation by PJA2. Nat. Commun. 15, 4484 (2024).","journal-title":"Nat. Commun."},{"key":"2539_CR157","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.3390\/v13122379","volume":"13","author":"IJ Ezeonwumelu","year":"2021","unstructured":"Ezeonwumelu, I. J., Garcia-Vidal, E. & Ballana, E. JAK-STAT pathway: A novel target to tackle viral infections. Viruses 13, 2379 (2021).","journal-title":"Viruses"},{"key":"2539_CR158","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.3389\/fimmu.2018.03086","volume":"9","author":"HS Chiang","year":"2019","unstructured":"Chiang, H. S. & Liu, H. M. The molecular basis of viral inhibition of IRF- and STAT-dependent immune responses. Front. Immunol. 9, 3086 (2019).","journal-title":"Front. Immunol."},{"key":"2539_CR159","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19849-9","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. \u03b2-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion. Nat. Commun. 11, 6000 (2020).","journal-title":"Nat. Commun."},{"key":"2539_CR160","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05176-7","volume":"9","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Downregulated NDR1 protein kinase inhibits innate immune response by initiating a miR146a-STAT1 feedback loop. Nat. Commun. 9, 2789 (2018).","journal-title":"Nat. Commun."},{"key":"2539_CR161","doi-asserted-by":"publisher","first-page":"998584","DOI":"10.3389\/fcimb.2022.998584","volume":"12","author":"MC Lee","year":"2022","unstructured":"Lee, M. C. et al. Influenza A virus NS1 protein represses antiviral immune response by hijacking NF-\u03baB to mediate transcription of type III IFN. Front. Cell Infect. Microbiol. 12, 998584 (2022).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2539_CR162","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.3390\/ijms23095283","volume":"23","author":"M Gudowska-Sawczuk","year":"2022","unstructured":"Gudowska-Sawczuk, M. & Mroczko, B. The role of nuclear factor kappa B (NF-\u03baB) in development and treatment of COVID-19: Review. Int. J. Mol. Sci. 23, 5283 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2539_CR163","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo, Q. et al. NF-\u03baB in biology and targeted therapy: New insights and translational implications. Sig. Transduct. Target. Ther. 9, 53 (2024).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR164","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41392-021-00575-7","volume":"6","author":"Y Wu","year":"2021","unstructured":"Wu, Y. et al. RNA-induced liquid phase separation of SARS-CoV-2 nucleocapsid protein facilitates NF-\u03baB hyperactivation and inflammation. Sig. Transduct. Target. Ther. 6, 167 (2021).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR165","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.3390\/ijms20133328","volume":"20","author":"N Kelley","year":"2019","unstructured":"Kelley, N., Jeltema, D., Duan, Y. & He, Y. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 20, 3328 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"2539_CR166","doi-asserted-by":"publisher","first-page":"1309128","DOI":"10.3389\/fcimb.2023.1309128","volume":"13","author":"Z Yue","year":"2024","unstructured":"Yue, Z. et al. Regulation and functions of the NLRP3 inflammasome in RNA virus infection. Front. Cell Infect. Microbiol. 13, 1309128 (2024).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2539_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1579-0","volume":"10","author":"LS Da Costa","year":"2019","unstructured":"Da Costa, L. S., Outlioua, A., Anginot, A., Akarid, K. & Arnoult, D. RNA viruses promote activation of the NLRP3 inflammasome through cytopathogenic effect-induced potassium efflux. Cell Death. Dis. 10, 346 (2019).","journal-title":"Cell Death. Dis."},{"key":"2539_CR168","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2147\/JIR.S295706","volume":"14","author":"SM Choudhury","year":"2021","unstructured":"Choudhury, S. M., Ma, X., Abdullah, S. W. & Zheng, H. Activation and inhibition of the NLRP3 inflammasome by RNA viruses. J. Inflamm. Res. 14, 1145\u20131163 (2021).","journal-title":"J. Inflamm. Res."},{"key":"2539_CR169","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/ni.3015","volume":"15","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. RNA viruses promote activation of the NLRP3 inflammasome through a RIP1-RIP3-DRP1 signaling pathway. Nat. Immunol. 15, 1126\u20131133 (2014).","journal-title":"Nat. Immunol."},{"key":"2539_CR170","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1073\/pnas.1304432110","volume":"110","author":"HX Zhang","year":"2013","unstructured":"Zhang, H. X. et al. Rig-I regulates NF-\u03baB activity through binding to NF-\u03baB1 3\u2032-UTR mRNA. Proc. Natl. Acad. Sci. USA 110, 6459\u20136464 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2539_CR171","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41423-020-00602-7","volume":"18","author":"K Onomoto","year":"2021","unstructured":"Onomoto, K., Onoguchi, K. & Yoneyama, M. Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors. Cell Mol. Immunol. 18, 539\u2013555 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"2539_CR172","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3109\/10409238.2011.630974","volume":"47","author":"AM Bruns","year":"2012","unstructured":"Bruns, A. M. & Horvath, C. M. Activation of RIG-I-like receptor signal transduction. Crit. Rev. Biochem. Mol. Biol. 47, 194\u2013206 (2012).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"2539_CR173","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.dci.2014.09.008","volume":"48","author":"L Nie","year":"2015","unstructured":"Nie, L., Zhang, Y., Dong, W., Xiang, L. & Shao, J. Involvement of zebrafish RIG-I in NF-\u03baB and IFN signaling pathways: Insights into functional conservation of RIG-I in antiviral innate immunity. Dev. Comp. Immunol. 48, 95\u2013101 (2015).","journal-title":"Dev. Comp. Immunol."},{"key":"2539_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41028-9","volume":"14","author":"Q He","year":"2023","unstructured":"He, Q. et al. MAVS integrates glucose metabolism and RIG-I-like receptor signaling. Nat. Commun. 14, 5343 (2023).","journal-title":"Nat. Commun."},{"key":"2539_CR175","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1007\/s00705-021-05211-x","volume":"166","author":"S Anwar","year":"2021","unstructured":"Anwar, S., Ul Islam, K., Azmi, M. I. & Iqbal, J. cGAS\u2013STING-mediated sensing pathways in DNA and RNA virus infections: Crosstalk with other sensing pathways. Arch. Virol. 166, 3255\u20133268 (2021).","journal-title":"Arch. Virol."},{"key":"2539_CR176","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.it.2016.12.004","volume":"38","author":"A Zevini","year":"2017","unstructured":"Zevini, A., Olagnier, D. & Hiscott, J. Crosstalk between cytoplasmic RIG-I and STING sensing pathways. Trends Immunol. 38, 194\u2013205 (2017).","journal-title":"Trends Immunol."},{"key":"2539_CR177","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni.3558","volume":"17","author":"Q Chen","year":"2016","unstructured":"Chen, Q., Sun, L. & Chen, Z. J. Regulation and function of the cGAS\u2013STING pathway of cytosolic DNA sensing. Nat. Immunol. 17, 1142\u20131149 (2016).","journal-title":"Nat. Immunol."},{"key":"2539_CR178","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610, 373\u2013380 (2022).","journal-title":"Nature"},{"key":"2539_CR179","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-023-01420-9","volume":"8","author":"S Cai","year":"2023","unstructured":"Cai, S. et al. Phase-separated nucleocapsid protein of SARS-CoV-2 suppresses cGAS-DNA recognition by disrupting cGAS-G3BP1 complex. Sig. Transduct. Target. Ther. 8, 170 (2023).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR180","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tips.2014.06.004","volume":"35","author":"K Wisskirchen","year":"2014","unstructured":"Wisskirchen, K., Lucifora, J., Michler, T. & Protzer, U. New pharmacological strategies to fight enveloped viruses. Trends Pharmacol. Sci. 35, 470\u2013478 (2014).","journal-title":"Trends Pharmacol. Sci."},{"key":"2539_CR181","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nbt.3367","volume":"34","author":"BA Kidd","year":"2016","unstructured":"Kidd, B. A. et al. Mapping the effects of drugs on the immune system. Nat. Biotechnol. 34, 47\u201356 (2016).","journal-title":"Nat. Biotechnol."},{"key":"2539_CR182","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","volume":"22","author":"A Von Delft","year":"2023","unstructured":"Von Delft, A. et al. Accelerating antiviral drug discovery: Lessons from COVID-19. Nat. Rev. Drug Discov. 22, 585\u2013603 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR183","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s42003-024-06130-8","volume":"7","author":"L Du","year":"2024","unstructured":"Du, L. et al. A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells. Commun. Biol. 7, 486 (2024).","journal-title":"Commun. Biol."},{"key":"2539_CR184","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41584-022-00904-2","volume":"19","author":"JJ Miner","year":"2023","unstructured":"Miner, J. J. & Fitzgerald, K. A. A path toward personalized medicine for autoinflammatory and related diseases. Nat. Rev. Rheumatol. 19, 182\u2013189 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2539_CR185","doi-asserted-by":"publisher","first-page":"R488","DOI":"10.1016\/j.cub.2011.05.039","volume":"21","author":"EMY Moresco","year":"2011","unstructured":"Moresco, E. M. Y., LaVine, D. & Beutler, B. Toll-like receptors. Curr. Biol. 21, R488\u2013R493 (2011).","journal-title":"Curr. Biol."},{"key":"2539_CR186","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cytogfr.2011.02.001","volume":"22","author":"M Yu","year":"2011","unstructured":"Yu, M. & Levine, S. J. Toll-like receptor 3, RIG-I-like receptors and the NLRP3 inflammasome: Key modulators of innate immune responses to double-stranded RNA viruses. Cytokine Growth Factor Rev. 22, 63\u201372 (2011).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2539_CR187","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.coi.2012.11.001","volume":"25","author":"SY Zhang","year":"2013","unstructured":"Zhang, S. Y. et al. TLR3 immunity to infection in mice and humans. Curr. Opin. Immunol. 25, 19\u201333 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"2539_CR188","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 11, 373\u2013384 (2010).","journal-title":"Nat. Immunol."},{"key":"2539_CR189","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","volume":"144","author":"RE Lanford","year":"2013","unstructured":"Lanford, R. E. et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 144, 1508\u20131517.e10 (2013).","journal-title":"Gastroenterology"},{"key":"2539_CR190","doi-asserted-by":"crossref","unstructured":"Steinmetzer, T. & Hardes, K. The antiviral potential of host protease inhibitors. Activation of Viruses by Host Proteases 279\u2013325 (2018).","DOI":"10.1007\/978-3-319-75474-1_11"},{"key":"2539_CR191","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.3390\/v12121423","volume":"12","author":"M Tampere","year":"2020","unstructured":"Tampere, M. et al. Novel broad-spectrum antiviral inhibitors targeting host factors essential for replication of pathogenic RNA viruses. Viruses 12, 1423 (2020).","journal-title":"Viruses"},{"key":"2539_CR192","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41422-021-00581-y","volume":"32","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. Comparison of viral RNA\u2013host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Cell Res 32, 9\u201323 (2022).","journal-title":"Cell Res"},{"key":"2539_CR193","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrd4336","volume":"13","author":"J Eder","year":"2014","unstructured":"Eder, J., Sedrani, R. & Wiesmann, C. The discovery of first-in-class drugs: Origins and evolution. Nat. Rev. Drug Discov. 13, 577\u2013587 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR194","doi-asserted-by":"publisher","first-page":"103581","DOI":"10.1016\/j.drudis.2023.103581","volume":"28","author":"S Zhao","year":"2023","unstructured":"Zhao, S., Zhang, X., Da Silva-J\u00fanior, E. F., Zhan, P. & Liu, X. Computer-aided drug design in seeking viral capsid modulators. Drug Discov. Today 28, 103581 (2023).","journal-title":"Drug Discov. Today"},{"key":"2539_CR195","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","volume":"616","author":"AV Sadybekov","year":"2023","unstructured":"Sadybekov, A. V. & Katritch, V. Computational approaches streamlining drug discovery. Nature 616, 673\u2013685 (2023).","journal-title":"Nature"},{"key":"2539_CR196","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3389\/fchem.2020.00343","volume":"8","author":"EHB Maia","year":"2020","unstructured":"Maia, E. H. B., Assis, L. C., De Oliveira, T. A., Da Silva, A. M. & Taranto, A. G. Structure-based virtual screening: From classical to artificial intelligence. Front. Chem. 8, 343 (2020).","journal-title":"Front. Chem."},{"key":"2539_CR197","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/s42003-023-04866-3","volume":"6","author":"L Shen","year":"2023","unstructured":"Shen, L., Feng, H., Qiu, Y. & Wei, G. W. SVSBI: Sequence-based virtual screening of biomolecular interactions. Commun. Biol. 6, 536 (2023).","journal-title":"Commun. Biol."},{"key":"2539_CR198","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/j.cell.2024.02.034","volume":"187","author":"Z Chen","year":"2024","unstructured":"Chen, Z. et al. Flexible scaffold-based cheminformatics approach for polypharmacological drug design. Cell 187, 2194\u20132208 (2024).","journal-title":"Cell"},{"key":"2539_CR199","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae563","volume":"40","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. Structure-inclusive similarity based directed GNN: A method that can control information flow to predict drug\u2013target binding affinity. Bioinformatics 40, btae563 (2024).","journal-title":"Bioinformatics"},{"key":"2539_CR200","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57485-3","volume":"16","author":"JL Yu","year":"2025","unstructured":"Yu, J. L. et al. Knowledge-guided diffusion model for 3D ligand-pharmacophore mapping. Nat. Commun. 16, 2269 (2025).","journal-title":"Nat. Commun."},{"key":"2539_CR201","doi-asserted-by":"publisher","first-page":"105740","DOI":"10.1016\/j.antiviral.2023.105740","volume":"220","author":"PP Parvatikar","year":"2023","unstructured":"Parvatikar, P. P. et al. Artificial intelligence: Machine learning approach for screening large database and drug discovery. Antivir. Res. 220, 105740 (2023).","journal-title":"Antivir. Res."},{"key":"2539_CR202","doi-asserted-by":"publisher","first-page":"2403998","DOI":"10.1002\/advs.202403998","volume":"11","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Conformational space profiling enhances generic molecular representation for AI-powered ligand-based drug discovery. Adv. Sci. 11, 2403998 (2024).","journal-title":"Adv. Sci."},{"key":"2539_CR203","unstructured":"Patel, H. & Sengupta, D. Antiviral drug target identification and ligand discovery. Comput. Drug Discov. Design 1\u201320 (2024). https:\/\/link.springer.com\/book\/10.1007\/978-1-0716-3441-7."},{"key":"2539_CR204","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13321-023-00703-1","volume":"15","author":"S Jung","year":"2023","unstructured":"Jung, S., Vatheuer, H. & Czodrowski, P. VSFlow: An open-source ligand-based virtual screening tool. J. Cheminform. 15, 40 (2023).","journal-title":"J. Cheminform."},{"key":"2539_CR205","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1038\/s41596-023-00885-w","volume":"18","author":"VK Tran-Nguyen","year":"2023","unstructured":"Tran-Nguyen, V. K., Junaid, M., Simeon, S. & Ballester, P. J. A practical guide to machine-learning scoring for structure-based virtual screening. Nat. Protoc. 18, 3460\u20133511 (2023).","journal-title":"Nat. Protoc."},{"key":"2539_CR206","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.2174\/156802612804547371","volume":"12","author":"J Mortier","year":"2012","unstructured":"Mortier, J., Rakers, C., Fr\u00e9d\u00e9rick, R. & Wolber, G. Computational tools for in silico fragment-based drug design. Curr. Top. Med. Chem. 12, 1935\u20131943 (2012).","journal-title":"Curr. Top. Med. Chem."},{"key":"2539_CR207","doi-asserted-by":"publisher","first-page":"133952","DOI":"10.1016\/j.molstruc.2022.133952","volume":"1270","author":"S Nakkala","year":"2022","unstructured":"Nakkala, S. et al. Identification of new anticancer agents against CENTERIN: Structure-based virtual screening, AutoDock and binding free energy studies. J. Mol. Struct. 1270, 133952 (2022).","journal-title":"J. Mol. Struct."},{"key":"2539_CR208","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1021\/acs.jmedchem.4c02074","volume":"68","author":"HR Lagiakos","year":"2025","unstructured":"Lagiakos, H. R. et al. In silico enabled discovery of KAI-11101, a preclinical DLK inhibitor for the treatment of neurodegenerative disease and neuronal injury. J. Med. Chem. 68, 2720\u20132741 (2025).","journal-title":"J. Med. Chem."},{"key":"2539_CR209","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1021\/acs.jcim.4c00621","volume":"64","author":"C Shen","year":"2024","unstructured":"Shen, C. et al. DrugFlow: An AI-driven one-stop platform for innovative drug discovery. J. Chem. Inf. Model. 64, 5381\u20135391 (2024).","journal-title":"J. Chem. Inf. Model."},{"key":"2539_CR210","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1039\/D3SC05552C","volume":"15","author":"H Cai","year":"2024","unstructured":"Cai, H. et al. CarsiDock: A deep learning paradigm for accurate protein\u2013ligand docking and screening based on large-scale pretraining. Chem. Sci. 15, 1449 (2024).","journal-title":"Chem. Sci."},{"key":"2539_CR211","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s42256-023-00712-7","volume":"5","author":"O Zhang","year":"2023","unstructured":"Zhang, O. et al. ResGen is a pocket-aware 3D molecular generation model based on parallel multiscale modeling. Nat. Mach. Intell. 5, 1020\u20131030 (2023).","journal-title":"Nat. Mach. Intell."},{"key":"2539_CR212","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/s43588-023-00511-5","volume":"3","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Efficient and accurate large library ligand docking with KarmaDock. Nat. Comput. Sci. 3, 789\u2013804 (2023).","journal-title":"Nat. Comput. Sci."},{"key":"2539_CR213","doi-asserted-by":"publisher","first-page":"10691","DOI":"10.1021\/acs.jmedchem.2c00991","volume":"65","author":"C Shen","year":"2022","unstructured":"Shen, C. et al. Boosting protein\u2013ligand binding pose prediction and virtual screening based on residue\u2013atom distance likelihood potential and graph transformer. J. Med. Chem. 65, 10691\u201310706 (2022).","journal-title":"J. Med. Chem."},{"key":"2539_CR214","doi-asserted-by":"publisher","first-page":"101520","DOI":"10.1016\/j.xcrp.2023.101520","volume":"4","author":"Q Ye","year":"2023","unstructured":"Ye, Q. et al. Integrating multimodal deep learning on knowledge graph for the discovery of synergistic drug combinations against infectious diseases. Cell Rep. Phys. Sci. 4, 101520 (2023).","journal-title":"Cell Rep. Phys. Sci."},{"key":"2539_CR215","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd4366","volume":"13","author":"JG Moffat","year":"2014","unstructured":"Moffat, J. G., Rudolph, J. & Bailey, D. Phenotypic screening in cancer drug discovery \u2014 past, present and future. Nat. Rev. Drug Discov. 13, 588\u2013602 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR216","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02291-7","volume":"20","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. An international consensus on the essential and desirable criteria for an \u2018organized\u2019 cancer screening programme. BMC Med 20, 101 (2022).","journal-title":"BMC Med"},{"key":"2539_CR217","doi-asserted-by":"publisher","first-page":"E422","DOI":"10.1503\/cmaj.171154","volume":"190","author":"MJ Dobrow","year":"2018","unstructured":"Dobrow, M. J., Ma, V. H., Chafe, R., Sullivan, T. & Rabeneck, L. Consolidated principles for screening based on a systematic review and consensus process. CMAJ 190, E422\u2013E429 (2018).","journal-title":"CMAJ"},{"key":"2539_CR218","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5582\/irdr.2023.01005","volume":"12","author":"\u00c7 Fidan","year":"2023","unstructured":"Fidan, \u00c7 et al. Carrier screening programs for rare diseases in developed countries and the case of Turkey: A systematic review. Intractable Rare Dis. Res. 12, 161\u2013169 (2023).","journal-title":"Intractable Rare Dis. Res."},{"key":"2539_CR219","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3390\/ijms25021014","volume":"25","author":"C Bombieri","year":"2024","unstructured":"Bombieri, C. et al. Advanced cellular models for rare disease study: Exploring neural, muscle and skeletal organoids. Int. J. Mol. Sci. 25, 1014 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2539_CR220","doi-asserted-by":"crossref","unstructured":"Sreelatha, H. V., Patel, S. & Nagarajan, P. The key concepts of animal models. Animal Models in Research: Principles and Practice 3\u201316 (2024).","DOI":"10.1007\/978-981-97-0048-6_1"},{"key":"2539_CR221","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s44222-023-00063-3","volume":"1","author":"A Loewa","year":"2023","unstructured":"Loewa, A., Feng, J. J. & Hedtrich, S. Human disease models in drug development. Nat. Rev. Bioeng. 1, 545\u2013559 (2023).","journal-title":"Nat. Rev. Bioeng."},{"key":"2539_CR222","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/pharmaceutics15061630","volume":"15","author":"A Ahmad","year":"2023","unstructured":"Ahmad, A., Imran, M. & Ahsan, H. Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics 15, 1630 (2023).","journal-title":"Pharmaceutics"},{"key":"2539_CR223","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/MLR.0000000000000640","volume":"55","author":"JR Desai","year":"2017","unstructured":"Desai, J. R. et al. Utilization of positive and negative controls to examine comorbid associations in observational database studies. Med. Care. 55, 244\u2013251 (2017).","journal-title":"Med. Care."},{"key":"2539_CR224","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/md16080279","volume":"16","author":"OM Lage","year":"2018","unstructured":"Lage, O. M. et al. Current screening methodologies in drug discovery for selected human diseases. Mar. Drugs 16, 279 (2018).","journal-title":"Mar. Drugs"},{"key":"2539_CR225","doi-asserted-by":"publisher","first-page":"bbab138","DOI":"10.1093\/bib\/bbab138","volume":"22","author":"J Fu","year":"2021","unstructured":"Fu, J. et al. Pharmacometabonomics: Data processing and statistical analysis. Brief. Bioinform. 22, bbab138 (2021).","journal-title":"Brief. Bioinform."},{"key":"2539_CR226","doi-asserted-by":"publisher","first-page":"7250","DOI":"10.3390\/ijms22147250","volume":"22","author":"D Kringel","year":"2021","unstructured":"Kringel, D., Malkusch, S. & L\u00f6tsch, J. Drugs and epigenetic molecular functions. A pharmacological data scientometric analysis. Int. J. Mol. Sci. 22, 7250 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2539_CR227","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.chembiol.2020.08.009","volume":"27","author":"F Vincent","year":"2020","unstructured":"Vincent, F. et al. Hit triage and validation in phenotypic screening: Considerations and strategies. Cell Chem. Biol. 27, 1332\u20131346 (2020).","journal-title":"Cell Chem. Biol."},{"key":"2539_CR228","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/adt.2017.796","volume":"15","author":"D Haasen","year":"2017","unstructured":"Haasen, D. et al. How phenotypic screening influenced drug discovery: Lessons from five years of practice. ASSAY Drug Dev. Technol. 15, 239\u2013246 (2017).","journal-title":"ASSAY Drug Dev. Technol."},{"key":"2539_CR229","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/psp4.12072","volume":"5","author":"J L\u00f6tsch","year":"2016","unstructured":"L\u00f6tsch, J. & Ultsch, A. Process pharmacology a pharmacological data science approach to drug. CPT Pharm. Syst. Pharma. 5, 192\u2013200 (2016).","journal-title":"CPT Pharm. Syst. Pharma."},{"key":"2539_CR230","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52980-5","volume":"15","author":"A Ianevski","year":"2024","unstructured":"Ianevski, A. et al. Single-cell transcriptomes identify patient-tailored therapies for selective coinhibition of cancer clones. Nat. Commun. 15, 8579 (2024).","journal-title":"Nat. Commun."},{"key":"2539_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-024-05976-3","volume":"25","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Drug\u2013target interaction prediction by integrating heterogeneous information with mutual attention network. BMC Bioinforma. 25, 361 (2024).","journal-title":"BMC Bioinforma."},{"key":"2539_CR232","first-page":"103","volume":"92","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. Diffusion mapping of drug targets on disease signaling network elements reveals drug combination strategies. Pac. Symp. Biocomput. 92, 103 (2018).","journal-title":"Pac. Symp. Biocomput."},{"key":"2539_CR233","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1101\/sqb.2016.81.031096","volume":"81","author":"E Manchado","year":"2016","unstructured":"Manchado, E. et al. A pipeline for drug target identification and validation. Cold Spring Harb. Symp. Quant. Biol. 81, 257\u2013267 (2016).","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"2539_CR234","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s43588-024-00737-x","volume":"4","author":"A Schneuing","year":"2024","unstructured":"Schneuing, A. et al. Structure-based drug design with equivariant diffusion models. Nat. Comput. Sci. 4, 899\u2013909 (2024).","journal-title":"Nat. Comput. Sci."},{"key":"2539_CR235","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.apsb.2019.05.004","volume":"9","author":"S Wang","year":"2019","unstructured":"Wang, S., Dong, G. & Sheng, C. Structural simplification: An efficient strategy in lead optimization. Acta Pharm. Sin. B 9, 880\u2013901 (2019).","journal-title":"Acta Pharm. Sin. B"},{"key":"2539_CR236","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1124\/jpet.119.257113","volume":"370","author":"PM Glassman","year":"2019","unstructured":"Glassman, P. M. & Muzykantov, V. R. Pharmacokinetic and pharmacodynamic properties of drug delivery systems. J. Pharmacol. Exp. Ther. 370, 570\u2013580 (2019).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2539_CR237","doi-asserted-by":"publisher","first-page":"102450","DOI":"10.1016\/j.nantod.2024.102450","volume":"58","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Optimizing structural design in SN38 delivery: More assembly stability and activation efficiency. Nano. Today 58, 102450 (2024).","journal-title":"Nano. Today"},{"key":"2539_CR238","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.toxlet.2007.07.010","volume":"173","author":"C Shi","year":"2007","unstructured":"Shi, C. et al. NMR-spectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats. Toxicol. Lett. 173, 161\u2013167 (2007).","journal-title":"Toxicol. Lett."},{"key":"2539_CR239","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3851\/IMP2152","volume":"17","author":"XY Wang","year":"2012","unstructured":"Wang, X. Y. et al. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations. Antivir. Ther. 17, 793\u2013803 (2012).","journal-title":"Antivir. Ther."},{"key":"2539_CR240","doi-asserted-by":"publisher","first-page":"379","DOI":"10.4155\/fmc-2022-0309","volume":"15","author":"Y Cheng","year":"2023","unstructured":"Cheng, Y., Zhong, C., Yan, S., Chen, C. & Gao, X. Structure modification: A successful tool for prodrug design. Future Med. Chem. 15, 379\u2013393 (2023).","journal-title":"Future Med. Chem."},{"key":"2539_CR241","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bph.17302","volume":"182","author":"Z Bereczki","year":"2025","unstructured":"Bereczki, Z. et al. Mitigating off-target effects of small RNAs: Conventional approaches, network theory and artificial intelligence. Br. J. Pharmacol. 182, 340\u2013379 (2025).","journal-title":"Br. J. Pharmacol."},{"key":"2539_CR242","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1021\/jm100863x","volume":"53","author":"MJ Sofia","year":"2010","unstructured":"Sofia, M. J. et al. Discovery of a \u03b2-d-2\u2032-Deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 53, 7202\u20137218 (2010).","journal-title":"J. Med. Chem."},{"key":"2539_CR243","doi-asserted-by":"publisher","first-page":"13121","DOI":"10.3390\/ijms252313121","volume":"25","author":"K Wu","year":"2024","unstructured":"Wu, K. et al. Overcoming challenges in small-molecule drug bioavailability: A review of key factors and approaches. Int. J. Mol. Sci. 25, 13121 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2539_CR244","doi-asserted-by":"publisher","first-page":"15537","DOI":"10.1021\/acs.jmedchem.4c01187","volume":"67","author":"MS Youse","year":"2024","unstructured":"Youse, M. S. et al. Optimization of ethoxzolamide analogs with improved pharmacokinetic properties for in vivo efficacy against Neisseria gonorrheae. J. Med. Chem. 67, 15537\u201315556 (2024).","journal-title":"J. Med. Chem."},{"key":"2539_CR245","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45641-0","volume":"15","author":"JF Standing","year":"2024","unstructured":"Standing, J. F. et al. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients. Nat. Commun. 15, 1652 (2024).","journal-title":"Nat. Commun."},{"key":"2539_CR246","doi-asserted-by":"publisher","first-page":"35947","DOI":"10.1039\/D3RA06476J","volume":"13","author":"M Rahban","year":"2023","unstructured":"Rahban, M. et al. Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry. RSC Adv. 13, 35947 (2023).","journal-title":"RSC Adv."},{"key":"2539_CR247","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/pharmaceutics15010124","volume":"15","author":"I Nugrahani","year":"2023","unstructured":"Nugrahani, I., Sulaiman, M. R., Eda, C., Uekusa, H. & Ibrahim, S. Stability and antibiotic potency improvement of levofloxacin by producing new salts with 2,6- and 3,5-dihydroxybenzoic acid and their comprehensive structural study. Pharmaceutics 15, 124 (2023).","journal-title":"Pharmaceutics"},{"key":"2539_CR248","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ph15101283","volume":"15","author":"OA Musaimi","year":"2022","unstructured":"Musaimi, O. A., Lombardi, L., Williams, D. R. & Albericio, F. Strategies for improving peptide stability and delivery. Pharmaceuticals 15, 1283 (2022).","journal-title":"Pharmaceuticals"},{"key":"2539_CR249","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40506-024-00281-2","volume":"17","author":"S Goswami","year":"2025","unstructured":"Goswami, S., Veeramachaneni, S. & Masurkar, P. P. Lenacapavir for HIV PrEP: Narrative review of clinical trials and implications for patient access. Curr. Treat. Options Infect. Dis. 17, 5 (2025).","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"2539_CR250","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cbpa.2020.01.005","volume":"55","author":"J Li","year":"2020","unstructured":"Li, J., Amatunia, A. & Renata, H. Recent advances in the chemoenzymatic synthesis of bioactive natural products. Curr. Opin. Chem. Biol. 55, 111\u2013118 (2020).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"2539_CR251","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.apsb.2023.11.021","volume":"14","author":"T Huo","year":"2024","unstructured":"Huo, T. et al. Late-stage modification of bioactive compounds: Improving druggability through efficient molecular editing. Acta Pharm. Sin. B 14, 1030\u20131076 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"2539_CR252","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2024.106227","volume":"179","author":"N Rustamova","year":"2024","unstructured":"Rustamova, N. et al. Modification of natural compounds through biotransformation process by microorganisms and their pharmacological properties. Fitoterapia 179, 106227 (2024).","journal-title":"Fitoterapia"},{"key":"2539_CR253","doi-asserted-by":"publisher","first-page":"117051","DOI":"10.1016\/j.ejmech.2024.117051","volume":"283","author":"B Feng","year":"2025","unstructured":"Feng, B., Yu, H., Dong, X., D\u00edaz-Holgu\u00edn, A. & Hu, H. Identification of bioactive compounds with popular single-atom modifications: Comprehensive analysis and implications for compound design. Eur. J. Med. Chem. 283, 117051 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"2539_CR254","doi-asserted-by":"publisher","first-page":"109100","DOI":"10.1016\/j.inoche.2021.109100","volume":"135","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Synthesis of aspirin catalyzed by supramolecular compound based on Keggin-type phosphomolybates with flexible 1,3-bis(4-pyridyl)propane. Inorg. Chem. Commun. 135, 109100 (2022).","journal-title":"Inorg. Chem. Commun."},{"key":"2539_CR255","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46697-8","volume":"15","author":"L Guillemard","year":"2024","unstructured":"Guillemard, L., Ackermann, L. & Johansson, M. J. Late-stage meta-C\u2013H alkylation of pharmaceuticals to modulate biological properties and expedite molecular optimization in a single step. Nat. Commun. 15, 3349 (2024).","journal-title":"Nat. Commun."},{"key":"2539_CR256","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jiec.2021.07.018","volume":"103","author":"Z Khan","year":"2021","unstructured":"Khan, Z. et al. Current developments in esterification reaction: A review on process and parameters. J. Ind. Eng. Chem. 103, 80\u2013101 (2021).","journal-title":"J. Ind. Eng. Chem."},{"key":"2539_CR257","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41586-023-06613-4","volume":"623","author":"J Woo","year":"2023","unstructured":"Woo, J., Stein, C., Christian, A. H. & Levin, M. D. Carbon-to-nitrogen single-atom transmutation of azaarenes. Nature 623, 77\u201383 (2023).","journal-title":"Nature"},{"key":"2539_CR258","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1016\/j.tetlet.2018.06.029","volume":"59","author":"A Deepthi","year":"2018","unstructured":"Deepthi, A., Sathi, V. & Nair, V. Recent topics of radical-based carbon\u2012carbon bond formations. Tetrahedron Lett. 59, 2767\u20132777 (2018).","journal-title":"Tetrahedron Lett."},{"key":"2539_CR259","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41586-024-08271-6","volume":"636","author":"EA Newcombe","year":"2024","unstructured":"Newcombe, E. A. et al. Stereochemistry in the disorder\u2013order continuum of protein interactions. Nature 636, 762\u2013768 (2024).","journal-title":"Nature"},{"key":"2539_CR260","first-page":"4644","volume":"5","author":"K Singh","year":"2014","unstructured":"Singh, K. et al. Stereochemistry and its role in drug design. IJPSR 5, 4644\u20134659 (2014).","journal-title":"IJPSR"},{"key":"2539_CR261","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2174\/1570163816666190502101803","volume":"17","author":"K Gandhi","year":"2020","unstructured":"Gandhi, K., Shah, U. & Patel, S. Drug stereochemistry: A prodigy for pharmacology and drug development. Curr. Drug Discov. Technol. 17, 565\u2013573 (2020).","journal-title":"Curr. Drug Discov. Technol."},{"key":"2539_CR262","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/s41557-024-01629-3","volume":"16","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Stereoselective and site-divergent synthesis of C-glycosides. Nat. Chem. 16, 2054\u20132065 (2024).","journal-title":"Nat. Chem."},{"key":"2539_CR263","doi-asserted-by":"publisher","first-page":"116547","DOI":"10.1016\/j.ejmech.2024.116547","volume":"275","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity. Eur. J. Med. Chem. 275, 116547 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2539_CR264","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrd.2018.116","volume":"17","author":"J Bostr\u00f6m","year":"2018","unstructured":"Bostr\u00f6m, J., Brown, D. G., Young, R. J. & Keser\u00fc, G. M. Expanding the medicinal chemistry synthetic toolbox. Nat. Rev. Drug Discov. 17, 709\u2013727 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR265","doi-asserted-by":"publisher","first-page":"108239","DOI":"10.1016\/j.biotechadv.2023.108239","volume":"68","author":"J Aminian-Dehkordi","year":"2023","unstructured":"Aminian-Dehkordi, J. et al. Synthetic biology tools for environmental protection. Biotechnol. Adv. 68, 108239 (2023).","journal-title":"Biotechnol. Adv."},{"key":"2539_CR266","doi-asserted-by":"publisher","unstructured":"Liu, S., Dai, H., Zhao, Y. & Liu, P. Preference optimization for molecule synthesis with conditional residual energy-based models. https:\/\/doi.org\/10.48550\/arXiv.2406.02066 (2024).","DOI":"10.48550\/arXiv.2406.02066"},{"key":"2539_CR267","doi-asserted-by":"crossref","unstructured":"Kayser, O. Natural substances as starting materials for drug synthesis. From the Maluku to Molecules: How Natural Substances Write History 307\u2013354 (2024).","DOI":"10.1007\/978-3-662-69923-2_8"},{"key":"2539_CR268","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.scowo.2024.100029","volume":"4","author":"S Ahmad","year":"2024","unstructured":"Ahmad, S., Jaiswal, R., Yadav, R. & Verma, S. Recent advances in green chemistry approaches for pharmaceutical synthesis. Sustain. Chem. One World 4, 100029 (2024).","journal-title":"Sustain. Chem. One World"},{"key":"2539_CR269","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54457-x","volume":"15","author":"Y Ruan","year":"2024","unstructured":"Ruan, Y. et al. An automatic end-to-end chemical synthesis development platform powered by large language models. Nat. Commun. 15, 10160 (2024).","journal-title":"Nat. Commun."},{"key":"2539_CR270","doi-asserted-by":"publisher","unstructured":"Garcia, E. et al. Cell-line-based studies of nanotechnology drug-delivery systems: A brief review. Nanocarriers Drug Delivery 375\u2013393 (2019). https:\/\/doi.org\/10.1016\/B978-0-12-814033-8.00012-6.","DOI":"10.1016\/B978-0-12-814033-8.00012-6"},{"key":"2539_CR271","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45444-3","volume":"15","author":"AI Leonov","year":"2024","unstructured":"Leonov, A. I. et al. An integrated self-optimizing programmable chemical synthesis and reaction engine. Nat. Commun. 15, 1240 (2024).","journal-title":"Nat. Commun."},{"key":"2539_CR272","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1021\/acscentsci.8b00357","volume":"4","author":"H Gao","year":"2018","unstructured":"Gao, H. et al. Using machine learning to predict suitable conditions for organic reactions. ACS Cent. Sci. 4, 1465\u20131476 (2018).","journal-title":"ACS Cent. Sci."},{"key":"2539_CR273","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1021\/acs.chemrev.2c00798","volume":"123","author":"CJ Taylor","year":"2023","unstructured":"Taylor, C. J. et al. A brief introduction to chemical reaction optimization. Chem. Rev. 123, 3089\u20133126 (2023).","journal-title":"Chem. Rev."},{"key":"2539_CR274","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1021\/acsmedchemlett.9b00491","volume":"11","author":"N Weeranoppanant","year":"2020","unstructured":"Weeranoppanant, N. & Adamo, A. In-line purification: A key component to facilitate drug synthesis and process development in medicinal chemistry. ACS Med. Chem. Lett. 11, 9\u201315 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"2539_CR275","first-page":"3","volume":"10","author":"N Perez","year":"2024","unstructured":"Perez, N. Isolation and purification techniques in natural products chemistry. J. Pharmacogn. Nat. Prod. 10, 3 (2024).","journal-title":"J. Pharmacogn. Nat. Prod."},{"key":"2539_CR276","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bib\/bbab391","volume":"23","author":"J Dong","year":"2022","unstructured":"Dong, J., Zhao, M., Liu, Y., Su, Y. & Zeng, X. Deep learning in retrosynthesis planning: datasets, models and tools. Brief. Bioinform. 23, 1\u201315 (2022).","journal-title":"Brief. Bioinform."},{"key":"2539_CR277","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13321-024-00936-8","volume":"16","author":"H Kim","year":"2024","unstructured":"Kim, H., Ryu, S., Jung, N., Yang, J. & Seok, C. CSearch: Chemical space search via virtual synthesis and global optimization. J. Cheminform. 16, 137 (2024).","journal-title":"J. Cheminform."},{"key":"2539_CR278","doi-asserted-by":"publisher","first-page":"106329","DOI":"10.1016\/j.bioorg.2022.106329","volume":"131","author":"Y Xiao","year":"2023","unstructured":"Xiao, Y. et al. Synthesis, antiproliferative and anti-MDR activities of lathyrane diterpene derivatives based on configuration inversion strategy. Bioorg. Chem. 131, 106329 (2023).","journal-title":"Bioorg. Chem."},{"key":"2539_CR279","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28857-w","volume":"13","author":"UV Ucak","year":"2022","unstructured":"Ucak, U. V., Ashyrmamatov, I., Ko, J. & Lee, J. Retrosynthetic reaction pathway prediction through neural machine translation of atomic environments. Nat. Commun. 13, 1186 (2022).","journal-title":"Nat. Commun."},{"key":"2539_CR280","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cclet.2017.09.061","volume":"29","author":"W Song","year":"2018","unstructured":"Song, W. et al. Applications of controlled inversion strategies in carbohydrate synthesis. Chin. Chem. Lett. 29, 27\u201334 (2018).","journal-title":"Chin. Chem. Lett."},{"key":"2539_CR281","doi-asserted-by":"publisher","first-page":"132584","DOI":"10.1016\/j.tet.2021.132584","volume":"104","author":"MA Hardy","year":"2022","unstructured":"Hardy, M. A., Nan, B., Wiest, O. & Sarpong, R. Strategic elements in computer-assisted retrosynthesis: A case study of the pupukeanane natural products. Tetrahedron 104, 132584 (2022).","journal-title":"Tetrahedron"},{"key":"2539_CR282","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3389\/fphar.2020.00420","volume":"11","author":"RJ Tyson","year":"2020","unstructured":"Tyson, R. J. et al. Precision dosing priority criteria: Drug, disease, and patient population variables. Front. Pharm. 11, 420 (2020).","journal-title":"Front. Pharm."},{"key":"2539_CR283","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/17512433.2018.1501271","volume":"11","author":"TM Polasek","year":"2018","unstructured":"Polasek, T. M., Shakib, S. & Rostami-Hodjegan, A. Precision dosing in clinical medicine: Present and future. Expert Rev. Clin. Pharmacol. 11, 743\u2013746 (2018).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"2539_CR284","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.2174\/1567201818666210609161301","volume":"18","author":"S Ashique","year":"2021","unstructured":"Ashique, S., Sandhu, N. K., Chawla, V. & Chawla, P. A. Targeted drug delivery: Trends and perspectives. Curr. Drug Deliv. 18, 1435\u20131455 (2021).","journal-title":"Curr. Drug Deliv."},{"key":"2539_CR285","doi-asserted-by":"publisher","first-page":"103659","DOI":"10.1016\/j.jddst.2022.103659","volume":"75","author":"AN Yawalkar","year":"2022","unstructured":"Yawalkar, A. N., Pawar, M. A. & Vavia, P. R. Microspheres for targeted drug delivery- A review on recent applications. J. Drug Deliv. Sci. Tec. 75, 103659 (2022).","journal-title":"J. Drug Deliv. Sci. Tec."},{"key":"2539_CR286","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","volume":"17","author":"H Wen","year":"2015","unstructured":"Wen, H., Jung, H. & Li, X. Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges. AAPS J. 17, 1327\u20131340 (2015).","journal-title":"AAPS J."},{"key":"2539_CR287","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.ymthe.2021.10.009","volume":"30","author":"R Zhang","year":"2022","unstructured":"Zhang, R. et al. sEVsRVG selectively delivers antiviral siRNA to fetus brain, inhibits ZIKV infection and mitigates ZIKV-induced microcephaly in mouse model. Mol. Ther. 30, 2078\u20132091 (2022).","journal-title":"Mol. Ther."},{"key":"2539_CR288","doi-asserted-by":"publisher","first-page":"116614","DOI":"10.1016\/j.bmc.2022.116614","volume":"56","author":"B Das","year":"2022","unstructured":"Das, B., Baidya, A. T. K., Mathew, A. T., Yadav, A. K. & Kumar, R. Structural modification aimed for improving solubility of lead compounds in early phase drug discovery. Bioorg. Med. Chem. 56, 116614 (2022).","journal-title":"Bioorg. Med. Chem."},{"key":"2539_CR289","doi-asserted-by":"publisher","first-page":"121375","DOI":"10.1016\/j.ijpharm.2021.121375","volume":"613","author":"A Bongioanni","year":"2022","unstructured":"Bongioanni, A., Bueno, M. S., Mezzano, B. A., Longhi, M. R. & Garnero, C. Amino acids and its pharmaceutical applications: A mini review. Int. J. Pharm. 613, 121375 (2022).","journal-title":"Int. J. Pharm."},{"key":"2539_CR290","doi-asserted-by":"publisher","first-page":"105103","DOI":"10.1016\/j.jddst.2023.105103","volume":"90","author":"R Kumar","year":"2023","unstructured":"Kumar, R., Kaur, C., Kaur, K., Khurana, N. & Singh, G. Prodrugs: Harnessing chemical modifications for improved therapeutics. J. Drug Deliv. Sci. Tec. 90, 105103 (2023).","journal-title":"J. Drug Deliv. Sci. Tec."},{"key":"2539_CR291","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1021\/acs.jmedchem.3c01801","volume":"67","author":"M Li","year":"2024","unstructured":"Li, M. et al. Molecular pharmacology profiling of phenylfentanil and its analogues to understand the putative involvement of an adrenergic mechanism in fentanyl-induced respiratory depression. J. Med. Chem. 67, 603\u2013619 (2024).","journal-title":"J. Med. Chem."},{"key":"2539_CR292","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","volume":"12","author":"B Yu","year":"2019","unstructured":"Yu, B. & Liu, D. Antibody\u2012drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J. Hematol. Oncol. 12, 94 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"2539_CR293","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/bcp.12988","volume":"82","author":"B Zhao","year":"2016","unstructured":"Zhao, B. et al. Brentuximab vedotin, an antibody\u2013drug conjugate, in patients with CD30-positive hematologic malignancies and hepatic or renal impairment. Brit. J. Clin. Pharmacol. 82, 696\u2013705 (2016).","journal-title":"Brit. J. Clin. Pharmacol."},{"key":"2539_CR294","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.xphs.2023.10.026","volume":"113","author":"VS Ayyar","year":"2024","unstructured":"Ayyar, V. S. & Song, D. Mechanistic pharmacokinetics and pharmacodynamics of GalNAc-siRNA: Translational model involving competitive receptor-mediated disposition and RISC-dependent gene silencing applied to givosiran. J. Pharm. Sci. 113, 176\u2013190 (2024).","journal-title":"J. Pharm. Sci."},{"key":"2539_CR295","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer, A. D. & Dowdy, S. F. GalNAc-siRNA conjugates: Leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 28, 109\u2013118 (2018).","journal-title":"Nucleic Acid Ther."},{"key":"2539_CR296","doi-asserted-by":"publisher","first-page":"105864","DOI":"10.1016\/j.phrs.2021.105864","volume":"173","author":"L Thangamani","year":"2021","unstructured":"Thangamani, L. et al. GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics. Pharmacol. Res. 173, 105864 (2021).","journal-title":"Pharmacol. Res."},{"key":"2539_CR297","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jconrel.2022.05.056","volume":"348","author":"H Ding","year":"2022","unstructured":"Ding, H. et al. Preparation and application of pH-responsive drug delivery systems. J. Control. Release 348, 206\u2013238 (2022).","journal-title":"J. Control. Release"},{"key":"2539_CR298","doi-asserted-by":"crossref","unstructured":"Ran et al. Modification of microenvironmental pH of nanoparticles for enhanced solubility and oral bioavailability of poorly water-soluble celecoxib. Int J. Pharmaceut. 659, 124179 (2024).","DOI":"10.1016\/j.ijpharm.2024.124179"},{"key":"2539_CR299","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3389\/fphar.2018.00971","volume":"9","author":"M Durymanov","year":"2018","unstructured":"Durymanov, M. & Reineke, J. Non-viral delivery of nucleic acids: Insight into mechanisms of overcoming intracellular barriers. Front. Pharmacol. 9, 971 (2018).","journal-title":"Front. Pharmacol."},{"key":"2539_CR300","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","volume":"5","author":"AM Vargason","year":"2021","unstructured":"Vargason, A. M., Anselmo, A. C. & Mitragotri, S. The evolution of commercial drug delivery technologies. Nat. Biomed. Eng. 5, 951\u2013967 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"2539_CR301","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1042\/BST20150291","volume":"44","author":"OO Yeku","year":"2016","unstructured":"Yeku, O. O. & Brentjens, R. J. Armored CAR T cells: Utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell antitumor efficacy. Biochem. Soc. Trans. 44, 412\u2013418 (2016).","journal-title":"Biochem. Soc. Trans."},{"key":"2539_CR302","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum, T. et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov. 7, 1238\u20131247 (2017).","journal-title":"Cancer Discov."},{"key":"2539_CR303","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/v15030789","volume":"15","author":"G Campos-Gonzalez","year":"2023","unstructured":"Campos-Gonzalez, G., Martinez-Picado, J., Velasco-Hernandez, T. & Salgado, M. Opportunities for CAR-T-cell immunotherapy in HIV cure. Viruses 15, 789 (2023).","journal-title":"Viruses"},{"key":"2539_CR304","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","volume":"16","author":"JK Patra","year":"2018","unstructured":"Patra, J. K. et al. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnol. 16, 71 (2018).","journal-title":"J. Nanobiotechnol."},{"key":"2539_CR305","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52500-5","volume":"15","author":"J Liu","year":"2024","unstructured":"Liu, J. et al. Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours. Nat. Commun. 15, 8203 (2024).","journal-title":"Nat. Commun."},{"key":"2539_CR306","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","volume":"3","author":"S Senapati","year":"2018","unstructured":"Senapati, S., Mahanta, A. K., Kumar, S. & Maiti, P. Controlled drug delivery vehicles for cancer treatment and their performance. Sig. Transduct. Target. Ther. 3, 7 (2018).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR307","doi-asserted-by":"publisher","first-page":"20210217","DOI":"10.1002\/EXP.20210217","volume":"2","author":"LJ Kubiatowicz","year":"2022","unstructured":"Kubiatowicz, L. J., Mohapatra, A., Krishnan, N., Fang, R. H. & Zhang, L. mRNA nanomedicine: Design and recent applications. Exploration 2, 20210217 (2022).","journal-title":"Exploration"},{"key":"2539_CR308","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27493-0","volume":"12","author":"X Han","year":"2021","unstructured":"Han, X. et al. An ionizable lipid toolbox for RNA delivery. Nat. Commun. 12, 7233 (2021).","journal-title":"Nat. Commun."},{"key":"2539_CR309","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10118-024-3090-z","volume":"42","author":"SN Liu","year":"2024","unstructured":"Liu, S. N. et al. A dynamic covalent bonding-based nanoplatform for intracellular codelivery of protein drugs and chemotherapeutics with enhanced anticancer effect. Chin. J. Polym. Sci. 42, 559\u2013569 (2024).","journal-title":"Chin. J. Polym. Sci."},{"key":"2539_CR310","doi-asserted-by":"publisher","first-page":"136852","DOI":"10.1016\/j.foodchem.2023.136852","volume":"432","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Inclusion complexes of capsanthin with acyclic cucurbit[n]urils to improve its stability and antioxidant capacity. Food Chem. 432, 136852 (2024).","journal-title":"Food Chem."},{"key":"2539_CR311","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1021\/acs.oprd.9b00524","volume":"24","author":"M Baumann","year":"2020","unstructured":"Baumann, M., Moody, T. S., Smyth, M. & Wharry, S. A perspective on continuous flow chemistry in the pharmaceutical industry. Org. Process Res. Dev. 24, 1802\u20131813 (2020).","journal-title":"Org. Process Res. Dev."},{"key":"2539_CR312","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 A new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2539_CR313","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1039\/D2SC00670G","volume":"13","author":"L Bornewasser","year":"2022","unstructured":"Bornewasser, L., Domnick, C. & Kath-Schorr, S. Stronger together for in-cell translation: natural and unnatural base modified mRNA. Chem. Sci. 13, 4753\u20134761 (2022).","journal-title":"Chem. Sci."},{"key":"2539_CR314","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1002\/pol.20230403","volume":"61","author":"J Singh","year":"2023","unstructured":"Singh, J. & Nayak, P. pH -responsive polymers for drug delivery: Trends and opportunities. J. Polym. Sci. 61, 2828\u20132850 (2023).","journal-title":"J. Polym. Sci."},{"key":"2539_CR315","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.addr.2021.01.009","volume":"171","author":"TL Rapp","year":"2021","unstructured":"Rapp, T. L. & DeForest, C. A. Targeting drug delivery with light: A highly focused approach. Adv. Drug Deliv. Rev. 171, 94\u2013107 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2539_CR316","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52609-7","volume":"15","author":"J Wu","year":"2024","unstructured":"Wu, J. et al. Selective regulation of macrophage lipid metabolism via nanomaterials\u2019 surface chemistry. Nat. Commun. 15, 8349 (2024).","journal-title":"Nat. Commun."},{"key":"2539_CR317","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1126\/science.aaz7959","volume":"368","author":"JD Brown","year":"2020","unstructured":"Brown, J. D. et al. Structural basis for transcriptional start site control of HIV-1 RNA fate. Science 368, 413\u2013417 (2020).","journal-title":"Science"},{"key":"2539_CR318","doi-asserted-by":"publisher","first-page":"103805","DOI":"10.1016\/j.drudis.2023.103805","volume":"29","author":"KR Sharma","year":"2024","unstructured":"Sharma, K. R., Colvis, C. M., Rodgers, G. P. & Sheeley, D. M. Illuminating the druggable genome: Pathways to progress. Drug Discov. Today 29, 103805 (2024).","journal-title":"Drug Discov. Today"},{"key":"2539_CR319","doi-asserted-by":"publisher","first-page":"16951","DOI":"10.1021\/acs.jmedchem.4c01540","volume":"67","author":"S Du","year":"2024","unstructured":"Du, S., Liu, X., Hu, X. & Zhan, P. Viral protein dimerization quality control: A design strategy for a potential viral inhibitor. J. Med. Chem. 67, 16951\u201316966 (2024).","journal-title":"J. Med. Chem."},{"key":"2539_CR320","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev.biochem.78.082207.084029","volume":"78","author":"PM Colman","year":"2009","unstructured":"Colman, P. M. New antivirals and drug resistance. Annu. Rev. Biochem. 78, 95\u2013118 (2009).","journal-title":"Annu. Rev. Biochem."},{"key":"2539_CR321","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1919285","volume":"13","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro. mAbs 13, 1919285 (2021).","journal-title":"mAbs"},{"key":"2539_CR322","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101681","volume":"23","author":"OO Grygorenko","year":"2020","unstructured":"Grygorenko, O. O. et al. Generating multibillion chemical space of readily accessible screening compounds. iScience 23, 101681 (2020).","journal-title":"iScience"},{"key":"2539_CR323","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2111172118","volume":"118","author":"S Chamakuri","year":"2021","unstructured":"Chamakuri, S. et al. DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors. Proc. Natl. Acad. Sci. USA 118, e2111172118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2539_CR324","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s42004-023-00961-y","volume":"6","author":"R Jimmidi","year":"2023","unstructured":"Jimmidi, R. et al. DNA-encoded chemical libraries yield noncovalent and nonpeptidic SARS-CoV-2 main protease inhibitors. Commun. Chem. 6, 164 (2023).","journal-title":"Commun. Chem."},{"key":"2539_CR325","doi-asserted-by":"publisher","first-page":"21096","DOI":"10.1021\/jacs.2c07217","volume":"144","author":"SM Meyer","year":"2022","unstructured":"Meyer, S. M. et al. DNA-encoded library screening to inform design of a ribonuclease targeting chimera (RiboTAC). J. Am. Chem. Soc. 144, 21096\u201321102 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"2539_CR326","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1021\/acs.accounts.1c00391","volume":"54","author":"Y Goto","year":"2021","unstructured":"Goto, Y. & Suga, H. The RaPID platform for the discovery of pseudonatural macrocyclic peptides. Acc. Chem. Res. 54, 3604\u20133617 (2021).","journal-title":"Acc. Chem. Res."},{"key":"2539_CR327","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41557-023-01205-1","volume":"15","author":"T Miura","year":"2023","unstructured":"Miura, T. et al. In vitro selection of macrocyclic peptide inhibitors containing cyclic \u03b32,4-amino acids targeting the SARS-CoV-2 main protease. Nat. Chem. 15, 998\u20131005 (2023).","journal-title":"Nat. Chem."},{"key":"2539_CR328","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg7865","volume":"9","author":"V Chenthamarakshan","year":"2023","unstructured":"Chenthamarakshan, V. et al. Accelerating drug target inhibitor discovery with a deep generative foundation model. Sci. Adv. 9, eadg7865 (2023).","journal-title":"Sci. Adv."},{"key":"2539_CR329","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18709-w","volume":"11","author":"A Douangamath","year":"2020","unstructured":"Douangamath, A. et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat. Commun. 11, 5047 (2020).","journal-title":"Nat. Commun."},{"key":"2539_CR330","doi-asserted-by":"publisher","first-page":"eabf8711","DOI":"10.1126\/sciadv.abf8711","volume":"7","author":"M Schuller","year":"2021","unstructured":"Schuller, M. et al. Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking. Sci. Adv. 7, eabf8711 (2021).","journal-title":"Sci. Adv."},{"key":"2539_CR331","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1021\/jacs.1c08402","volume":"144","author":"A Luttens","year":"2022","unstructured":"Luttens, A. et al. Ultralarge virtual screening identifies SARS-CoV-2 main protease inhibitors with broad-spectrum activity against coronaviruses. J. Am. Chem. Soc. 144, 2905\u20132920 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"2539_CR332","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1021\/acs.jmedchem.2c02120","volume":"66","author":"I Singh","year":"2023","unstructured":"Singh, I. et al. Structure-based discovery of inhibitors of the SARS-CoV-2 Nsp14 N7-methyltransferase. J. Med. Chem. 66, 7785\u20137803 (2023).","journal-title":"J. Med. Chem."},{"key":"2539_CR333","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1126\/science.abf7945","volume":"372","author":"S G\u00fcnther","year":"2021","unstructured":"G\u00fcnther, S. et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science 372, 642\u2013646 (2021).","journal-title":"Science"},{"key":"2539_CR334","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1021\/acsmedchemlett.0c00521","volume":"11","author":"MM Ghahremanpour","year":"2020","unstructured":"Ghahremanpour, M. M. et al. Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2. ACS Med. Chem. Lett. 11, 2526\u20132533 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"2539_CR335","doi-asserted-by":"publisher","first-page":"101647","DOI":"10.1016\/j.tmaid.2020.101647","volume":"35","author":"Y Cao","year":"2020","unstructured":"Cao, Y., Deng, Q. & Dai, S. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel. Med. Infect. Dis. 35, 101647 (2020).","journal-title":"Travel. Med. Infect. Dis."},{"key":"2539_CR336","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30, 269\u2013271 (2020).","journal-title":"Cell Res"},{"key":"2539_CR337","doi-asserted-by":"publisher","first-page":"114239","DOI":"10.1016\/j.ejmech.2022.114239","volume":"234","author":"Y Hua","year":"2022","unstructured":"Hua, Y. et al. Drug repositioning: Progress and challenges in drug discovery for various diseases. Eur. J. Med. Chem. 234, 114239 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"2539_CR338","doi-asserted-by":"publisher","first-page":"e2212931120","DOI":"10.1073\/pnas.2212931120","volume":"120","author":"S Gahbauer","year":"2023","unstructured":"Gahbauer, S. et al. Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2. Proc. Natl. Acad. Sci. USA 120, e2212931120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2539_CR339","doi-asserted-by":"publisher","first-page":"18231","DOI":"10.1002\/anie.202105584","volume":"60","author":"F Sutanto","year":"2021","unstructured":"Sutanto, F. et al. Combining high-throughput synthesis and high-throughput protein crystallography for accelerated hit identification. Angew. Chem. Int. Ed. 60, 18231\u201318239 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR340","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1021\/acs.jmedchem.2c01681","volume":"66","author":"A Chopra","year":"2023","unstructured":"Chopra, A., Bauman, J. D., Ruiz, F. X. & Arnold, E. Halo library, a tool for rapid identification of ligand binding sites on proteins using crystallographic fragment screening. J. Med. Chem. 66, 6013\u20136024 (2023).","journal-title":"J. Med. Chem."},{"key":"2539_CR341","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23443-y","volume":"12","author":"D Bajusz","year":"2021","unstructured":"Bajusz, D. et al. Exploring protein hotspots by optimized fragment pharmacophores. Nat. Commun. 12, 3201 (2021).","journal-title":"Nat. Commun."},{"key":"2539_CR342","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25166-6","volume":"12","author":"JA Newman","year":"2021","unstructured":"Newman, J. A. et al. Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase. Nat. Commun. 12, 4848 (2021).","journal-title":"Nat. Commun."},{"key":"2539_CR343","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/nar\/gkac1207","volume":"51","author":"N Imprachim","year":"2023","unstructured":"Imprachim, N., Yosaatmadja, Y. & Newman, J. A. Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal details of exoribonuclease activation and mRNA capping and provide starting points for antiviral drug development. Nucleic Acids Res. 51, 475\u2013487 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2539_CR344","doi-asserted-by":"publisher","first-page":"19191","DOI":"10.1002\/anie.202103693","volume":"60","author":"S Sreeramulu","year":"2021","unstructured":"Sreeramulu, S. et al. Exploring the druggability of conserved RNA regulatory elements in the SARS-CoV-2 genome. Angew. Chem. Int. Ed. 60, 19191\u201319200 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR345","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/acscentsci.1c00039","volume":"7","author":"CH Zhang","year":"2021","unstructured":"Zhang, C. H. et al. Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations. ACS Cent. Sci. 7, 467\u2013475 (2021).","journal-title":"ACS Cent. Sci."},{"key":"2539_CR346","doi-asserted-by":"publisher","first-page":"8169","DOI":"10.1021\/acs.jmedchem.1c02174","volume":"65","author":"OA Davis","year":"2022","unstructured":"Davis, O. A. et al. Optimizing shape complementarity enables the discovery of potent tricyclic BCL6 inhibitors. J. Med. Chem. 65, 8169\u20138190 (2022).","journal-title":"J. Med. Chem."},{"key":"2539_CR347","doi-asserted-by":"publisher","first-page":"17992","DOI":"10.1021\/acs.jmedchem.1c01366","volume":"64","author":"H Ju","year":"2021","unstructured":"Ju, H. et al. Identification of C5-NH2 modified oseltamivir derivatives as novel influenza neuraminidase inhibitors with highly improved antiviral activities and favorable druggability. J. Med. Chem. 64, 17992\u201318009 (2021).","journal-title":"J. Med. Chem."},{"key":"2539_CR348","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32630-4","volume":"13","author":"MA Tye","year":"2022","unstructured":"Tye, M. A. et al. Elucidating the path to plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance. Nat. Commun. 13, 4976 (2022).","journal-title":"Nat. Commun."},{"key":"2539_CR349","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1002\/anie.201713172","volume":"57","author":"L Deshmukh","year":"2018","unstructured":"Deshmukh, L., Tugarinov, V., Appella, D. H. & Clore, G. M. Targeting a dark excited state of HIV-1 nucleocapsid by antiretroviral thioesters revealed by NMR spectroscopy. Angew. Chem. Int. Ed. 57, 2687\u20132691 (2018).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR350","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.1021\/acs.jmedchem.2c00170","volume":"65","author":"G Liu","year":"2022","unstructured":"Liu, G. et al. Crystallography-guided optimizations of the Keap1\u2013Nrf2 inhibitors on the solvent exposed region: from symmetric to asymmetric naphthalenesulfonamides. J. Med. Chem. 65, 8289\u20138302 (2022).","journal-title":"J. Med. Chem."},{"key":"2539_CR351","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","volume":"59","author":"D Kang","year":"2016","unstructured":"Kang, D. et al. Design, synthesis, and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 nonnucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles. J. Med. Chem. 59, 7991\u20138007 (2016).","journal-title":"J. Med. Chem."},{"key":"2539_CR352","doi-asserted-by":"publisher","first-page":"7315","DOI":"10.1021\/acs.jmedchem.7b00596","volume":"60","author":"XZ Zhao","year":"2017","unstructured":"Zhao, X. Z. et al. Structure-guided optimization of HIV integrase strand transfer inhibitors. J. Med. Chem. 60, 7315\u20137332 (2017).","journal-title":"J. Med. Chem."},{"key":"2539_CR353","doi-asserted-by":"publisher","first-page":"9375","DOI":"10.1021\/acs.jmedchem.9b00359","volume":"62","author":"G Wu","year":"2019","unstructured":"Wu, G. et al. Overview of recent strategic advances in medicinal chemistry. J. Med. Chem. 62, 9375\u20139414 (2019).","journal-title":"J. Med. Chem."},{"key":"2539_CR354","doi-asserted-by":"publisher","first-page":"115474","DOI":"10.1016\/j.ejmech.2023.115474","volume":"256","author":"M Hausdorff","year":"2023","unstructured":"Hausdorff, M. et al. Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases. Eur. J. Med. Chem. 256, 115474 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"2539_CR355","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.1021\/acs.jmedchem.2c00120","volume":"65","author":"R Ahmed-Belkacem","year":"2022","unstructured":"Ahmed-Belkacem, R. et al. Potent inhibition of SARS-CoV-2 nsp14 N7-methyltransferase by sulfonamide-based bisubstrate analogs. J. Med. Chem. 65, 6231\u20136249 (2022).","journal-title":"J. Med. Chem."},{"key":"2539_CR356","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","volume":"121","author":"ME Cilento","year":"2021","unstructured":"Cilento, M. E., Kirby, K. A. & Sarafianos, S. G. Avoiding drug resistance in HIV reverse transcriptase. Chem. Rev. 121, 3271\u20133296 (2021).","journal-title":"Chem. Rev."},{"key":"2539_CR357","doi-asserted-by":"publisher","first-page":"8062","DOI":"10.1021\/acs.jmedchem.9b00838","volume":"62","author":"LN Rusere","year":"2019","unstructured":"Rusere, L. N. et al. HIV-1 protease inhibitors incorporating stereochemically defined P2\u2032 ligands to optimize hydrogen bonding in the substrate envelope. J. Med. Chem. 62, 8062\u20138079 (2019).","journal-title":"J. Med. Chem."},{"key":"2539_CR358","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1021\/acs.jmedchem.8b01925","volume":"62","author":"MR Bauer","year":"2019","unstructured":"Bauer, M. R. & Mackey, M. D. Electrostatic complementarity as a fast and effective tool to optimize binding and selectivity of protein\u2013ligand complexes. J. Med. Chem. 62, 3036\u20133050 (2019).","journal-title":"J. Med. Chem."},{"key":"2539_CR359","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","volume":"183","author":"TM Clausen","year":"2020","unstructured":"Clausen, T. M. et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183, 1043\u20131057.e15 (2020).","journal-title":"Cell"},{"key":"2539_CR360","doi-asserted-by":"publisher","first-page":"15870","DOI":"10.1002\/anie.202102717","volume":"60","author":"C Nie","year":"2021","unstructured":"Nie, C. et al. Polysulfates block SARS-CoV-2 uptake through electrostatic interactions. Angew. Chem. Int. Ed. 60, 15870\u201315878 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR361","doi-asserted-by":"publisher","first-page":"eabo5083","DOI":"10.1126\/sciadv.abo5083","volume":"8","author":"GJ Correy","year":"2022","unstructured":"Correy, G. J. et al. The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and X-ray diffraction at room temperature. Sci. Adv. 8, eabo5083 (2022).","journal-title":"Sci. Adv."},{"key":"2539_CR362","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.chembiol.2021.05.018","volume":"28","author":"D Zaidman","year":"2021","unstructured":"Zaidman, D. et al. An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor. Cell Chem. Biol. 28, 1795\u20131806.e5 (2021).","journal-title":"Cell Chem. Biol."},{"key":"2539_CR363","doi-asserted-by":"publisher","first-page":"14702","DOI":"10.1021\/acs.jmedchem.1c01214","volume":"64","author":"AK Ghosh","year":"2021","unstructured":"Ghosh, A. K. et al. Indole chloropyridinyl ester-derived SARS-CoV-2 3CLpro inhibitors: Enzyme inhibition, antiviral efficacy, structure\u2013activity relationship, and X-ray structural studies. J. Med. Chem. 64, 14702\u201314714 (2021).","journal-title":"J. Med. Chem."},{"key":"2539_CR364","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1021\/acsptsci.2c00203","volume":"6","author":"P Sahoo","year":"2023","unstructured":"Sahoo, P. et al. Detailed insights into the inhibitory mechanism of new ebselen derivatives against main protease (Mpro) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). ACS Pharmacol. Transl. Sci. 6, 171\u2013180 (2023).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2539_CR365","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1021\/acs.jmedchem.6b01021","volume":"60","author":"C Nitsche","year":"2017","unstructured":"Nitsche, C. et al. Peptide\u2013boronic acid inhibitors of flaviviral proteases: Medicinal chemistry and structural biology. J. Med. Chem. 60, 511\u2013516 (2017).","journal-title":"J. Med. Chem."},{"key":"2539_CR366","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.chembiol.2024.02.012","volume":"31","author":"WM McFadden","year":"2024","unstructured":"McFadden, W. M. et al. Identification of clickable HIV-1 capsid-targeting probes for viral replication inhibition. Cell Chem. Biol. 31, 477\u2013486.e7 (2024).","journal-title":"Cell Chem. Biol."},{"key":"2539_CR367","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1021\/jacs.3c10581","volume":"146","author":"JR Ramsey","year":"2024","unstructured":"Ramsey, J. R. et al. Using a function-first \u201cscout fragment\u201d-based approach to develop allosteric covalent inhibitors of conformationally dynamic helicase mechanoenzymes. J. Am. Chem. Soc. 146, 62\u201367 (2024).","journal-title":"J. Am. Chem. Soc."},{"key":"2539_CR368","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17997-6","volume":"11","author":"WH Guo","year":"2020","unstructured":"Guo, W. H. et al. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. Nat. Commun. 11, 4268 (2020).","journal-title":"Nat. Commun."},{"key":"2539_CR369","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1021\/jacs.8b11027","volume":"141","author":"E Mons","year":"2019","unstructured":"Mons, E. et al. The alkyne moiety as a latent electrophile in irreversible covalent small molecule inhibitors of cathepsin K. J. Am. Chem. Soc. 141, 3507\u20133514 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"2539_CR370","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.1021\/jacs.1c13568","volume":"144","author":"C Borsari","year":"2022","unstructured":"Borsari, C. et al. Covalent proximity scanning of a distal cysteine to target PI3K. J. Am. Chem. Soc. 144, 6326\u20136342 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"2539_CR371","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.1021\/acs.jmedchem.3c01825","volume":"67","author":"L Hillebrand","year":"2024","unstructured":"Hillebrand, L., Liang, X. J., Serafim, R. A. M. & Gehringer, M. Emerging and re-emerging warheads for targeted covalent inhibitors: An update. J. Med. Chem. 67, 7668\u20137758 (2024).","journal-title":"J. Med. Chem."},{"key":"2539_CR372","doi-asserted-by":"publisher","first-page":"11194","DOI":"10.1021\/acs.chemrev.8b00369","volume":"118","author":"VL Schramm","year":"2018","unstructured":"Schramm, V. L. Enzymatic transition states and drug design. Chem. Rev. 118, 11194\u201311258 (2018).","journal-title":"Chem. Rev."},{"key":"2539_CR373","first-page":"203","volume":"389","author":"M Potempa","year":"2015","unstructured":"Potempa, M., Lee, S. K., Wolfenden, R. & Swanstrom, R. The triple threat of HIV-1 protease inhibitors. Curr. Top. Microbiol. Immunol. 389, 203\u2013241 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"2539_CR374","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1073\/pnas.1202808109","volume":"109","author":"DR Kipp","year":"2012","unstructured":"Kipp, D. R., Hirschi, J. S., Wakata, A., Goldstein, H. & Schramm, V. L. Transition states of native and drug-resistant HIV-1 protease are the same. Proc. Natl. Acad. Sci. USA 109, 6543\u20136548 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2539_CR375","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1021\/acsmedchemlett.9b00670","volume":"11","author":"AK Ghosh","year":"2020","unstructured":"Ghosh, A. K. et al. Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors with P2-carboxamide functionalities. ACS Med. Chem. Lett. 11, 1965\u20131972 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"2539_CR376","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/cphc.201001050","volume":"12","author":"J Leblond","year":"2011","unstructured":"Leblond, J. & Petitjean, A. Molecular tweezers: Concepts and applications. ChemPhysChem 12, 1043\u20131051 (2011).","journal-title":"ChemPhysChem"},{"key":"2539_CR377","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1021\/acs.jpcb.5b00692","volume":"119","author":"X Zheng","year":"2015","unstructured":"Zheng, X., Liu, D., Klar, F. G. & Bowers, M. T. Amyloid \u03b2\u2011protein assembly: The effect of molecular tweezers CLR01 and CLR03. J. Phys. Chem. B 119, 4831\u20134841 (2015).","journal-title":"J. Phys. Chem. B"},{"key":"2539_CR378","doi-asserted-by":"publisher","first-page":"17024","DOI":"10.1021\/jacs.0c06400","volume":"142","author":"T Weil","year":"2020","unstructured":"Weil, T. et al. Supramolecular mechanism of viral envelope disruption by molecular tweezers. J. Am. Chem. Soc. 142, 17024\u201317038 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"2539_CR379","first-page":"2187","volume":"2","author":"T Weil","year":"2022","unstructured":"Weil, T. et al. Advanced molecular tweezers with lipid anchors against SARS-CoV-2 and other respiratory viruses. J. Am. Chem. Soc. Au 2, 2187\u20132202 (2022).","journal-title":"J. Am. Chem. Soc. Au"},{"key":"2539_CR380","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1021\/acs.jmedchem.9b00303","volume":"62","author":"W Lu","year":"2019","unstructured":"Lu, W., Du, W., Somovilla, V. J., Yu, G. & Haksar, D. Enhanced inhibition of influenza a virus adhesion by di- and trivalent hemagglutinin inhibitors. J. Med. Chem. 62, 6398\u20136404 (2019).","journal-title":"J. Med. Chem."},{"key":"2539_CR381","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/nsmb.3271","volume":"23","author":"LJ Calder","year":"2016","unstructured":"Calder, L. J. & Rosenthal, P. B. Cryomicroscopy provides structural snapshots of influenza virus membrane fusion. Nat. Struct. Mol. Biol. 23, 853\u2013858 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2539_CR382","doi-asserted-by":"publisher","first-page":"15532","DOI":"10.1002\/anie.202004832","volume":"59","author":"C Nie","year":"2020","unstructured":"Nie, C. et al. Topology-matching design of an influenza-neutralizing spiky nanoparticle-based inhibitor with a dual mode of action. Angew. Chem. Int. Ed. 59, 15532\u201315536 (2020).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR383","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1039\/b313659k","volume":"33","author":"X Liang","year":"2004","unstructured":"Liang, X. & Sadler, P. J. Cyclam complexes and their applications in medicine. Chem. Soc. Rev. 33, 246\u2013266 (2004).","journal-title":"Chem. Soc. Rev."},{"key":"2539_CR384","doi-asserted-by":"publisher","first-page":"12436","DOI":"10.1093\/nar\/gkaa1053","volume":"48","author":"I Manfredonia","year":"2020","unstructured":"Manfredonia, I. et al. Genome-wide mapping of SARS-CoV-2 RNA structures identifies therapeutically relevant elements. Nucleic Acids Res 48, 12436\u201312452 (2020).","journal-title":"Nucleic Acids Res"},{"key":"2539_CR385","doi-asserted-by":"publisher","first-page":"18144","DOI":"10.1002\/anie.202104179","volume":"60","author":"L Melidis","year":"2021","unstructured":"Melidis, L. et al. Supramolecular cylinders target bulge structures in the 5\u2032 UTR of the RNA genome of SARS-CoV-2 and inhibit viral replication. Angew. Chem. Int. Ed. 60, 18144\u201318151 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR386","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.7150\/thno.81494","volume":"13","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo, A., Compte, M., \u00c1lvarez-Vallina, L. & Sanz, L. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics 13, 1028\u20131041 (2023).","journal-title":"Theranostics"},{"key":"2539_CR387","first-page":"285","volume":"2","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. Recent advances in the molecular design and applications of proteolysis targeting chimera-based multispecific antiviral modality. Acta Mater. Med. 2, 285\u2013298 (2023).","journal-title":"Acta Mater. Med."},{"key":"2539_CR388","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina, K. et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 113, 7124\u20137129 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2539_CR389","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","volume":"57","author":"AD Buhimschi","year":"2018","unstructured":"Buhimschi, A. D. et al. Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation. Biochemistry 57, 3564\u20133575 (2018).","journal-title":"Biochemistry"},{"key":"2539_CR390","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: An RTK case study. Cell Chem. Biol. 25, 67\u201377.e3 (2018).","journal-title":"Cell Chem. Biol."},{"key":"2539_CR391","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11429-w","volume":"10","author":"M de Wispelaere","year":"2019","unstructured":"de Wispelaere, M. et al. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. 10, 3468 (2019).","journal-title":"Nat. Commun."},{"key":"2539_CR392","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","volume":"62","author":"JM Pawlotsky","year":"2015","unstructured":"Pawlotsky, J. M., Feld, J. J., Zeuzem, S. & Hoofnagle, J. H. From non-A, non-B hepatitis to hepatitis C virus cure. J. Hepatol. 62, S87\u2013S99 (2015).","journal-title":"J. Hepatol."},{"key":"2539_CR393","doi-asserted-by":"publisher","first-page":"17508","DOI":"10.1074\/jbc.M313020200","volume":"279","author":"C Lin","year":"2004","unstructured":"Lin, C. et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 279, 17508\u201317514 (2004).","journal-title":"J. Biol. Chem."},{"key":"2539_CR394","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002832","volume":"8","author":"KP Romano","year":"2012","unstructured":"Romano, K. P. et al. The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors. PLoS Pathog. 8, e1002832 (2012).","journal-title":"PLoS Pathog."},{"key":"2539_CR395","doi-asserted-by":"publisher","first-page":"116202","DOI":"10.1016\/j.ejmech.2024.116202","volume":"268","author":"J Desantis","year":"2024","unstructured":"Desantis, J. et al. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity. Eur. J. Med. Chem. 268, 116202 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2539_CR396","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1021\/acschembio.3c00312","volume":"19","author":"PE Cockram","year":"2024","unstructured":"Cockram, P. E. et al. Allosteric inhibitors of the SARS-CoV-2 papain-like protease domain induce proteasomal degradation of its parent protein NSP3. ACS Chem. Biol. 19, 22\u201336 (2024).","journal-title":"ACS Chem. Biol."},{"key":"2539_CR397","doi-asserted-by":"publisher","first-page":"27248","DOI":"10.1021\/jacs.3c12678","volume":"145","author":"X Sang","year":"2023","unstructured":"Sang, X. et al. A chemical strategy for the degradation of the main protease of SARS-CoV-2 in cells. J. Am. Chem. Soc. 145, 27248\u201327253 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"2539_CR398","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","volume":"67","author":"YR Alugubelli","year":"2024","unstructured":"Alugubelli, Y. R. et al. Discovery of first-in-class PROTAC degraders of SARS-CoV-2 main protease. J. Med. Chem. 67, 6495\u20136507 (2024).","journal-title":"J. Med. Chem."},{"key":"2539_CR399","first-page":"1","volume":"31","author":"LA Emert-Sedlak","year":"2024","unstructured":"Emert-Sedlak, L. A. et al. PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication. Cell ChemBiol 31, 1\u201311 (2024).","journal-title":"Cell ChemBiol"},{"key":"2539_CR400","doi-asserted-by":"publisher","first-page":"678077","DOI":"10.3389\/fcell.2021.678077","volume":"9","author":"J Liu","year":"2021","unstructured":"Liu, J., Peng, Y. & Wei, W. Light-controllable PROTACs for temporospatial control of protein degradation. Front. Cell Dev. Biol. 9, 678077 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"2539_CR401","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41392-022-00999-9","volume":"7","author":"M He","year":"2022","unstructured":"He, M. et al. PROTACs: Great opportunities for academia and industry (an update from 2020 to 2021). Sig. Transduct. Target. Ther. 7, 181 (2022).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR402","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/acscentsci.2c01317","volume":"9","author":"ES Toriki","year":"2023","unstructured":"Toriki, E. S. et al. Rational chemical design of molecular glue degraders. ACS Cent. Sci. 9, 915\u2013926 (2023).","journal-title":"ACS Cent. Sci."},{"key":"2539_CR403","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19386-5","volume":"11","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. A universal dual mechanism immunotherapy for the treatment of influenza virus infections. Nat. Commun. 11, 5597 (2020).","journal-title":"Nat. Commun."},{"key":"2539_CR404","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/bjc.2015.435","volume":"114","author":"N Diamantis","year":"2016","unstructured":"Diamantis, N. & Banerji, U. Antibody\u2012drug conjugates\u2014an emerging class of cancer treatment. Brit. J. Cancer 114, 362\u2013367 (2016).","journal-title":"Brit. J. Cancer"},{"key":"2539_CR405","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1021\/ml400370w","volume":"5","author":"S Asano","year":"2014","unstructured":"Asano, S., Gavrilyuk, J., Burton, D. R. & Barbas, C. F. Preparation and activities of macromolecule conjugates of the CCR5 antagonist maraviroc. ACS Med. Chem. Lett. 5, 133\u2013137 (2014).","journal-title":"ACS Med. Chem. Lett."},{"key":"2539_CR406","doi-asserted-by":"publisher","first-page":"115294","DOI":"10.1016\/j.ejmech.2023.115294","volume":"252","author":"C Wang","year":"2023","unstructured":"Wang, C. et al. Multitargeted drug design strategy for discovery of short-peptide-based HIV-1 entry inhibitors with high potency. Eur. J. Med. Chem. 252, 115294 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"2539_CR407","doi-asserted-by":"publisher","first-page":"11460","DOI":"10.1021\/acs.jmedchem.1c00781","volume":"64","author":"C Wang","year":"2021","unstructured":"Wang, C. et al. A \u201cTwo-birds-one-stone\u201d Approach toward the design of bifunctional human immunodeficiency virus type 1 entry inhibitors targeting the CCR5 coreceptor and gp41 N-terminal heptad repeat region. J. Med. Chem. 64, 11460\u201311471 (2021).","journal-title":"J. Med. Chem."},{"key":"2539_CR408","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1021\/acscentsci.0c00984","volume":"6","author":"HS Haniff","year":"2020","unstructured":"Haniff, H. S. et al. Targeting the SARS-CoV-2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders. ACS Cent. Sci. 6, 1713\u20131721 (2020).","journal-title":"ACS Cent. Sci."},{"key":"2539_CR409","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.tips.2024.03.006","volume":"45","author":"S Kovachka","year":"2024","unstructured":"Kovachka, S., Tong, Y., Childs-Disney, J. L. & Disney, M. D. Heterobifunctional small molecules to modulate RNA function. Trends Pharmacol. Sci. 45, 449\u2013463 (2024).","journal-title":"Trends Pharmacol. Sci."},{"key":"2539_CR410","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1021\/acscentsci.3c00015","volume":"9","author":"S Mikutis","year":"2023","unstructured":"Mikutis, S. et al. Proximity-induced nucleic acid degrader (PINAD) approach to targeted rna degradation using small molecules. ACS Cent. Sci. 9, 892\u2013904 (2023).","journal-title":"ACS Cent. Sci."},{"key":"2539_CR411","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl4393","volume":"10","author":"Y Min","year":"2024","unstructured":"Min, Y. et al. Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera. Sci. Adv. 10, eadl4393 (2024).","journal-title":"Sci. Adv."},{"key":"2539_CR412","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1021\/acsinfecdis.8b00337","volume":"5","author":"L Yang","year":"2019","unstructured":"Yang, L. et al. Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives. ACS Infect. Dis. 5, 713\u2013724 (2019).","journal-title":"ACS Infect. Dis."},{"key":"2539_CR413","doi-asserted-by":"publisher","first-page":"2109580","DOI":"10.1002\/adma.202109580","volume":"34","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. A gradient pH-sensitive polymer-based antiviral strategy via viroporin-induced membrane acidification. Adv. Mater. 34, 2109580 (2022).","journal-title":"Adv. Mater."},{"key":"2539_CR414","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1517\/14728222.2012.665879","volume":"16","author":"L Brakier-Gingras","year":"2013","unstructured":"Brakier-Gingras, L., Charbonneau, J. & Butcher, S. E. Targeting frameshifting in the human immunodeficiency virus. Expert Opin. Ther. Targets 16, 249\u2013258 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"key":"2539_CR415","doi-asserted-by":"publisher","first-page":"e2023051118","DOI":"10.1073\/pnas.2023051118","volume":"118","author":"Y Sun","year":"2021","unstructured":"Sun, Y. et al. Restriction of SARS-CoV-2 replication by targeting programmed \u22121 ribosomal frameshifting. Proc. Natl. Acad. Sci. USA 118, e2023051118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2539_CR416","doi-asserted-by":"publisher","first-page":"eabl6096","DOI":"10.1126\/sciadv.abl6096","volume":"7","author":"M Zafferani","year":"2021","unstructured":"Zafferani, M. et al. Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures. Sci. Adv. 7, eabl6096 (2021).","journal-title":"Sci. Adv."},{"key":"2539_CR417","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/anie.202011419","volume":"60","author":"C Zhao","year":"2021","unstructured":"Zhao, C. et al. Targeting RNA G-quadruplex in SARS-CoV-2: A promising therapeutic target for COVID-19?. Angew. Chem. Int. Ed. 60, 432\u2013438 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR418","doi-asserted-by":"publisher","first-page":"802766","DOI":"10.3389\/fchem.2021.802766","volume":"9","author":"S Hegde","year":"2021","unstructured":"Hegde, S., Tang, Z., Zhao, J. & Wang, J. Inhibition of SARS-CoV-2 by targeting conserved viral RNA structures and sequences. Front. Chem. 9, 802766 (2021).","journal-title":"Front. Chem."},{"key":"2539_CR419","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009706","volume":"17","author":"C Prabhakara","year":"2021","unstructured":"Prabhakara, C. et al. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors. PLoS Pathog. 17, e1009706 (2021).","journal-title":"PLoS Pathog."},{"key":"2539_CR420","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.tim.2022.06.005","volume":"30","author":"H Li","year":"2022","unstructured":"Li, H. et al. Phase separation in viral infections. Trends Microbiol 30, 1217\u20131231 (2022).","journal-title":"Trends Microbiol"},{"key":"2539_CR421","doi-asserted-by":"publisher","first-page":"7115","DOI":"10.1074\/jbc.TM118.001192","volume":"294","author":"E Gomes","year":"2019","unstructured":"Gomes, E. & Shorter, J. The molecular language of membraneless organelles. J. Biol. Chem. 294, 7115\u20137127 (2019).","journal-title":"J. Biol. Chem."},{"key":"2539_CR422","first-page":"118831","volume":"1867","author":"Q Nevers","year":"2020","unstructured":"Nevers, Q., Albertini, A. A., Lagaudri\u00e8re-Gesbert, C. & Gaudin, Y. Negri bodies and other virus membrane-less replication compartments. BBA-Mol. Cell Res. 1867, 118831 (2020).","journal-title":"BBA-Mol. Cell Res."},{"key":"2539_CR423","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/v13030366","volume":"13","author":"T Etibor","year":"2021","unstructured":"Etibor, T., Yamauchi, Y. & Amorim, M. Liquid biomolecular condensates and viral lifecycles: review and perspectives. Viruses 13, 366 (2021).","journal-title":"Viruses"},{"key":"2539_CR424","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.1257037","volume":"346","author":"I Banerjee","year":"2014","unstructured":"Banerjee, I. et al. Influenza A virus uses the aggresome processing machinery for host cell entry. Science 346, 473\u2013477 (2014).","journal-title":"Science"},{"key":"2539_CR425","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/cells10061460","volume":"10","author":"O Dolnik","year":"2021","unstructured":"Dolnik, O., Gerresheim, G. K. & Biedenkopf, N. New perspectives on the biogenesis of viral inclusion bodies in negative-sense RNA virus infections. Cells 10, 1460 (2021).","journal-title":"Cells"},{"key":"2539_CR426","doi-asserted-by":"publisher","first-page":"e1009926","DOI":"10.1371\/journal.ppat.1009926","volume":"17","author":"N Lopez","year":"2021","unstructured":"Lopez, N. et al. Deconstructing virus condensation. PLoS Pathog. 17, e1009926 (2021).","journal-title":"PLoS Pathog."},{"key":"2539_CR427","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.molcel.2020.11.041","volume":"80","author":"C Iserman","year":"2020","unstructured":"Iserman, C. et al. Genomic RNA elements drive phase separation of the SARS-CoV-2 nucleocapsid. Mol. Cell 80, 1078\u20131091.e6 (2020).","journal-title":"Mol. Cell"},{"key":"2539_CR428","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41556-019-0300-y","volume":"21","author":"P Sengupta","year":"2019","unstructured":"Sengupta, P. et al. A lipid-based partitioning mechanism for selective incorporation of proteins into membranes of HIV particles. Nat. Cell Biol. 21, 452\u2013461 (2019).","journal-title":"Nat. Cell Biol."},{"key":"2539_CR429","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22297-8","volume":"12","author":"M Zhao","year":"2021","unstructured":"Zhao, M. et al. GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein. Nat. Commun. 12, 2114 (2021).","journal-title":"Nat. Commun."},{"key":"2539_CR430","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20768-y","volume":"12","author":"S Lu","year":"2021","unstructured":"Lu, S. et al. The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein. Nat. Commun. 12, 502 (2021).","journal-title":"Nat. Commun."},{"key":"2539_CR431","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007733","volume":"15","author":"M Ringel","year":"2019","unstructured":"Ringel, M. et al. Nipah virus induces two inclusion body populations: Identification of novel inclusions at the plasma membrane. PLoS Pathog. 15, e1007733 (2019).","journal-title":"PLoS Pathog."},{"key":"2539_CR432","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00655-9","volume":"8","author":"V Rincheval","year":"2017","unstructured":"Rincheval, V. et al. Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus. Nat. Commun. 8, 563 (2017).","journal-title":"Nat. Commun."},{"key":"2539_CR433","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/s41422-021-00504-x","volume":"31","author":"G Zhu","year":"2021","unstructured":"Zhu, G. et al. Pharmacological inhibition of SRC-1 phase separation suppresses YAP oncogenic transcription activity. Cell Res 31, 1028\u20131031 (2021).","journal-title":"Cell Res"},{"key":"2539_CR434","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/pathogens12020243","volume":"12","author":"Y Zheng","year":"2023","unstructured":"Zheng, Y. & Gao, C. Phase separation: The robust modulator of innate antiviral signaling and SARS-CoV-2 infection. Pathogens 12, 243 (2023).","journal-title":"Pathogens"},{"key":"2539_CR435","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s13238-021-00832-z","volume":"12","author":"D Zhao","year":"2021","unstructured":"Zhao, D. et al. Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2. Protein Cell 12, 734\u2013740 (2021).","journal-title":"Protein Cell"},{"key":"2539_CR436","doi-asserted-by":"publisher","first-page":"105115","DOI":"10.1016\/j.antiviral.2021.105115","volume":"192","author":"T Kashyap","year":"2021","unstructured":"Kashyap, T. et al. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo. Antivir. Res. 192, 105115 (2021).","journal-title":"Antivir. Res."},{"key":"2539_CR437","doi-asserted-by":"publisher","first-page":"884228","DOI":"10.3389\/fphar.2022.884228","volume":"13","author":"G Mostafa-Hedeab","year":"2022","unstructured":"Mostafa-Hedeab, G. et al. Selinexor and COVID-19: The neglected warden. Front. Pharmacol. 13, 884228 (2022).","journal-title":"Front. Pharmacol."},{"key":"2539_CR438","doi-asserted-by":"publisher","first-page":"103888","DOI":"10.1016\/j.drudis.2024.103888","volume":"29","author":"S Du","year":"2024","unstructured":"Du, S., Hu, X., Liu, X. & Zhan, P. Revolutionizing viral disease treatment: Phase separation and lysosome\/exosome targeting as new areas and new paradigms for antiviral drug research. Drug Discov. Today 29, 103888 (2024).","journal-title":"Drug Discov. Today"},{"key":"2539_CR439","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri3622","volume":"14","author":"PD Robbins","year":"2014","unstructured":"Robbins, P. D. & Morelli, A. E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14, 195\u2013208 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"2539_CR440","first-page":"237","volume":"15","author":"Q Wu","year":"2023","unstructured":"Wu, Q. et al. Presence of intact hepatitis B virions in exosomes. Cell. Mol. Gastroenter. 15, 237\u2013259 (2023).","journal-title":"Cell. Mol. Gastroenter."},{"key":"2539_CR441","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3389\/fmicb.2016.01765","volume":"7","author":"ML Pleet","year":"2016","unstructured":"Pleet, M. L. et al. Ebola VP40 in exosomes can cause immune cell dysfunction. Front. Microbiol. 7, 1765 (2016).","journal-title":"Front. Microbiol."},{"key":"2539_CR442","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.cell.2020.10.039","volume":"183","author":"S Ghosh","year":"2020","unstructured":"Ghosh, S. et al. \u03b2-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell 183, 1520\u20131535.e14 (2020).","journal-title":"Cell"},{"key":"2539_CR443","doi-asserted-by":"publisher","first-page":"eadv4033","DOI":"10.1126\/sciadv.adv4033","volume":"11","author":"TB Lear","year":"2025","unstructured":"Lear, T. B. et al. Inhibition of virally induced TFEB proteasomal degradation as a host-centric therapeutic approach for coronaviral infection. Sci. Adv. 11, eadv4033 (2025).","journal-title":"Sci. Adv."},{"key":"2539_CR444","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"2539_CR445","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn2038","volume":"15","author":"CJ Balibar","year":"2023","unstructured":"Balibar, C. J. et al. Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1. Sci. Transl. Med. 15, eabn2038 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2539_CR446","doi-asserted-by":"publisher","first-page":"11452","DOI":"10.1021\/acs.jmedchem.4c01345","volume":"67","author":"LD Pennington","year":"2024","unstructured":"Pennington, L. D. et al. Property-based drug design merits a nobel prize. J. Med. Chem. 67, 11452\u201311458 (2024).","journal-title":"J. Med. Chem."},{"key":"2539_CR447","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1021\/acs.jmedchem.0c00117","volume":"63","author":"D Kang","year":"2020","unstructured":"Kang, D. et al. Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties. J. Med. Chem. 63, 4837\u20134848 (2020).","journal-title":"J. Med. Chem."},{"key":"2539_CR448","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1021\/acs.jmedchem.8b01656","volume":"62","author":"D Kang","year":"2019","unstructured":"Kang, D. et al. Identification of dihydrofuro[3,4-d]pyrimidine derivatives as novel HIV-1 nonnucleoside reverse transcriptase inhibitors with promising antiviral activities and desirable physicochemical properties. J. Med. Chem. 62, 1484\u20131501 (2019).","journal-title":"J. Med. Chem."},{"key":"2539_CR449","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1021\/acs.jmedchem.8b01729","volume":"2","author":"B Huang","year":"2019","unstructured":"Huang, B. et al. Exploiting the tolerant region i of the nonnucleoside reverse transcriptase inhibitor (NNRTI) binding pocket: discovery of potent diarylpyrimidine-typed HIV-1 NNRTIs against Wild-Type and E138K mutant virus with significantly improved water solubility and favorable safety profiles. J. Med. Chem. 2, 2083\u20132098 (2019).","journal-title":"J. Med. Chem."},{"key":"2539_CR450","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1517\/17425255.2012.717614","volume":"8","author":"EA Thackaberry","year":"2012","unstructured":"Thackaberry, E. A. Nonclinical toxicological considerations for pharmaceutical salt selection. Expert Opin. Drug Metab. Toxicol. 8, 1419\u20131433 (2012).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"2539_CR451","doi-asserted-by":"publisher","first-page":"16426","DOI":"10.1021\/acs.jmedchem.3c01876","volume":"66","author":"S Gao","year":"2023","unstructured":"Gao, S. et al. Design, synthesis, and biological evaluation of trisubstituted piperazine derivatives as noncovalent severe acute respiratory syndrome coronavirus 2 main protease inhibitors with improved antiviral activity and favorable druggability. J. Med. Chem. 66, 16426\u201316440 (2023).","journal-title":"J. Med. Chem."},{"key":"2539_CR452","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1021\/acs.jmedchem.7b00083","volume":"60","author":"Z Qiu","year":"2017","unstructured":"Qiu, Z. et al. Discovery and preclinical characterization of third-generation 4-H heteroaryldihydropyrimidine (HAP) analogs as hepatitis B virus (HBV) capsid inhibitors. J. Med. Chem. 60, 3352\u20133371 (2017).","journal-title":"J. Med. Chem."},{"key":"2539_CR453","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1039\/C7CC01679D","volume":"53","author":"K Li","year":"2017","unstructured":"Li, K., Hou, J. T., Yang, J. & Yu, X. Q. A tumor-specific and mitochondrion-targeted fluorescent probe for real-time sensing of hypochlorite in living cells. Chem. Commun. 53, 5539 (2017).","journal-title":"Chem. Commun."},{"key":"2539_CR454","doi-asserted-by":"publisher","first-page":"14793","DOI":"10.1021\/acs.jmedchem.1c01365","volume":"64","author":"M Wang","year":"2021","unstructured":"Wang, M. et al. Development of asialoglycoprotein-mediated hepatocyte-targeting antitumor prodrugs triggered by glutathione. J. Med. Chem. 64, 14793\u201314808 (2021).","journal-title":"J. Med. Chem."},{"key":"2539_CR455","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1021\/jacs.5b09974","volume":"138","author":"MW Tibbitt","year":"2016","unstructured":"Tibbitt, M. W., Dahlman, J. E. & Langer, R. Emerging frontiers in drug delivery. J. Am. Chem. Soc. 138, 704\u2013717 (2016).","journal-title":"J. Am. Chem. Soc."},{"key":"2539_CR456","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acsmedchemlett.8b00586","volume":"10","author":"AS Alanazi","year":"2019","unstructured":"Alanazi, A. S., James, E. & Mehellou, Y. The ProTide prodrug technology: Where next?. ACS Med. Chem. Lett. 10, 2\u20135 (2019).","journal-title":"ACS Med. Chem. Lett."},{"key":"2539_CR457","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1021\/acsptsci.3c00050","volume":"6","author":"Y Liu","year":"2023","unstructured":"Liu, Y., Sun, S., Li, J., Wang, W. & Zhu, H. J. Cell-dependent activation of ProTide prodrugs and its implications in antiviral studies. ACS Pharmacol. Transl. Sci. 6, 1340\u20131346 (2023).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2539_CR458","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41557-022-00964-7","volume":"14","author":"L Dunsmore","year":"2022","unstructured":"Dunsmore, L. et al. Controlled masking and targeted release of redox-cycling ortho-quinones via a C\u2013C bond-cleaving 1,6-elimination. Nat. Chem. 14, 754\u2013765 (2022).","journal-title":"Nat. Chem."},{"key":"2539_CR459","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1021\/acs.molpharmaceut.2c00668","volume":"20","author":"E Lipka","year":"2023","unstructured":"Lipka, E. et al. NPP-669, a novel broad-spectrum antiviral therapeutic with excellent cellular uptake, antiviral potency, oral bioavailability, preclinical efficacy, and a promising safety margin. Mol. Pharma. 20, 370\u2013382 (2023).","journal-title":"Mol. Pharma."},{"key":"2539_CR460","doi-asserted-by":"publisher","first-page":"e202210001","DOI":"10.1002\/anie.202210001","volume":"61","author":"Q Gong","year":"2022","unstructured":"Gong, Q. et al. A carbon-carbon bond cleavage-based prodrug activation strategy applied to \u03b2-lapachone for cancer-specific targeting. Angew. Chem. Int. Ed. 61, e202210001 (2022).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR461","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/jm301580n","volume":"56","author":"J Jacobs","year":"2013","unstructured":"Jacobs, J. et al. Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. J. Med. Chem. 56, 534\u2013546 (2013).","journal-title":"J. Med. Chem."},{"key":"2539_CR462","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41586-022-05175-1","volume":"610","author":"Z Fan","year":"2022","unstructured":"Fan, Z. et al. Molecular editing of aza-arene C\u2013H bonds by distance, geometry and chirality. Nature 610, 87\u201393 (2022).","journal-title":"Nature"},{"key":"2539_CR463","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1021\/acsmedchemlett.3c00073","volume":"14","author":"M Jones","year":"2023","unstructured":"Jones, M. & Goodyear, R. L. High-throughput purification in drug discovery: scaling new heights of productivity. ACS Med. Chem. Lett. 14, 916\u2013919 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"2539_CR464","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1021\/acsmedchemlett.0c00093","volume":"11","author":"AW Dombrowski","year":"2020","unstructured":"Dombrowski, A. W. et al. Expanding the medicinal chemist toolbox: Comparing seven C(sp2)\u2013C(sp3) cross-coupling methods by library synthesis. ACS Med. Chem. Lett. 11, 597\u2013604 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"2539_CR465","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1021\/acsmedchemlett.2c00542","volume":"14","author":"MJR Bastidas","year":"2023","unstructured":"Bastidas, M. J. R., L\u2019Heureux, S., Liu, W., Lee, K. & El Marrouni, A. High-throughput photo- and electrochemical sp2\u2013sp3 cross-electrophile coupling to access novel tedizolid analogs. ACS Med. Chem. Lett. 14, 666\u2013671 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"2539_CR466","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1039\/D2CC06371A","volume":"59","author":"J Li","year":"2023","unstructured":"Li, J. et al. Synthesis of maleimide-braced peptide macrocycles and their potential anti-SARS-CoV-2 mechanisms. Chem. Commun. 59, 868\u2013871 (2023).","journal-title":"Chem. Commun."},{"key":"2539_CR467","doi-asserted-by":"publisher","first-page":"38691","DOI":"10.1039\/D1RA06963B","volume":"11","author":"T Tiyasakulchai","year":"2021","unstructured":"Tiyasakulchai, T. et al. Scalable synthesis of favipiravir via conventional and continuous flow chemistry. RSC Adv. 11, 38691\u201338693 (2021).","journal-title":"RSC Adv."},{"key":"2539_CR468","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1021\/acscentsci.1c00608","volume":"7","author":"JA McIntosh","year":"2021","unstructured":"McIntosh, J. A. et al. Engineered ribosyl-1-kinase enables concise synthesis of molnupiravir, an antiviral for COVID-19. ACS Cent. Sci. 7, 1980\u20131985 (2021).","journal-title":"ACS Cent. Sci."},{"key":"2539_CR469","doi-asserted-by":"publisher","first-page":"14292","DOI":"10.1039\/D2SC05182F","volume":"13","author":"AE McMillan","year":"2022","unstructured":"McMillan, A. E., Wu, W. W. X., Nichols, P. L., Wanner, B. M. & Bode, J. W. A vending machine for drug-like molecules \u2013 automated synthesis of virtual screening hits. Chem. Sci. 13, 14292\u201314299 (2022).","journal-title":"Chem. Sci."},{"key":"2539_CR470","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41573-023-00774-7","volume":"22","author":"MW Mullowney","year":"2023","unstructured":"Mullowney, M. W. et al. Artificial intelligence for natural product drug discovery. Nat. Rev. Drug. Discov. 22, 895\u2013916 (2023).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"2539_CR471","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"2539_CR472","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"2539_CR473","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001026","volume":"18","author":"AM Kloosterman","year":"2020","unstructured":"Kloosterman, A. M. et al. Expansion of RiPP biosynthetic space through integration of pangenomics and machine learning uncovers a novel class of lanthipeptides. PLoS Biol. 18, e3001026 (2020).","journal-title":"PLoS Biol."},{"key":"2539_CR474","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41592-019-0344-8","volume":"16","author":"K D\u00fchrkop","year":"2019","unstructured":"D\u00fchrkop, K. et al. SIRIUS 4: A rapid tool for turning tandem mass spectra into metabolite structure information. Nat. Methods 16, 299\u2013302 (2019).","journal-title":"Nat. Methods"},{"key":"2539_CR475","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1039\/D0SC00442A","volume":"11","author":"A Howarth","year":"2020","unstructured":"Howarth, A., Ermanis, K. & Goodman, J. M. DP4-AI automated NMR data analysis: straight from spectrometer to structure. Chem. Sci. 11, 4351 (2020).","journal-title":"Chem. Sci."},{"key":"2539_CR476","doi-asserted-by":"publisher","first-page":"12408","DOI":"10.1002\/anie.201605707","volume":"55","author":"G Schneider","year":"2016","unstructured":"Schneider, G. et al. Deorphaning the macromolecular targets of the natural anticancer compound doliculide. Angew. Chem. Int. Ed. 55, 12408\u201312411 (2016).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR477","doi-asserted-by":"publisher","first-page":"5457","DOI":"10.1021\/acs.jcim.0c00900","volume":"60","author":"CEM Schindler","year":"2020","unstructured":"Schindler, C. E. M. et al. Large-scale assessment of binding free energy calculations in active drug discovery projects. J. Chem. Inf. Model. 60, 5457\u20135474 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"2539_CR478","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39856-w","volume":"14","author":"L Chen","year":"2023","unstructured":"Chen, L. et al. Sequence-based drug design as a concept in computational drug design. Nat. Commun. 14, 4217 (2023).","journal-title":"Nat. Commun."},{"key":"2539_CR479","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/s41565-022-01174-5","volume":"17","author":"X Huang","year":"2022","unstructured":"Huang, X. et al. Nanotechnology-based strategies against SARS-CoV-2 variants. Nat. Nanotechnol. 17, 1027\u20131037 (2022).","journal-title":"Nat. Nanotechnol."},{"key":"2539_CR480","doi-asserted-by":"publisher","first-page":"9741","DOI":"10.1039\/D1CS00317H","volume":"50","author":"N Wang","year":"2021","unstructured":"Wang, N. et al. Chemical design principles of next-generation antiviral surface coatings. Chem. Soc. Rev. 50, 9741\u20139765 (2021).","journal-title":"Chem. Soc. Rev."},{"key":"2539_CR481","doi-asserted-by":"publisher","first-page":"101243","DOI":"10.1016\/j.nantod.2021.101243","volume":"40","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. TiO2 supported single Ag atoms nanozyme for elimination of SARS-CoV-2. Nano. Today 40, 101243 (2021).","journal-title":"Nano. Today"},{"key":"2539_CR482","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41392-024-02035-4","volume":"9","author":"X Sun","year":"2024","unstructured":"Sun, X., Setrerrahmane, S., Li, C., Hu, J. & Xu, H. Nucleic acid drugs: Recent progress and future perspectives. Sig. Transduct. Target. Ther. 9, 316 (2024).","journal-title":"Sig. Transduct. Target. Ther."},{"key":"2539_CR483","doi-asserted-by":"publisher","first-page":"103663","DOI":"10.1016\/j.drudis.2023.103663","volume":"28","author":"A Mahmoudi","year":"2023","unstructured":"Mahmoudi, A. et al. Harnessing aptamers against COVID-19: A therapeutic strategy. Drug Discov. Today 28, 103663 (2023).","journal-title":"Drug Discov. Today"},{"key":"2539_CR484","doi-asserted-by":"publisher","first-page":"10266","DOI":"10.1002\/anie.202100225","volume":"60","author":"M Sun","year":"2021","unstructured":"Sun, M. et al. Aptamer blocking strategy inhibits SARS-CoV-2 virus infection. Angew. Chem. Int. Ed. 60, 10266\u201310272 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"2539_CR485","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1093\/nar\/gkab1293","volume":"50","author":"PR Gruenke","year":"2022","unstructured":"Gruenke, P. R. et al. Selection and identification of an RNA aptamer that specifically binds the HIV-1 capsid lattice and inhibits viral replication. Nucleic Acids Res. 50, 1701\u20131717 (2022).","journal-title":"Nucleic Acids Res"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02539-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02539-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02539-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:03:56Z","timestamp":1771977836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02539-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":485,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2539"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02539-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}